[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 47 of about 47
1. Zucchetto A, Bruzzone S, De Paoli A, Regine V, Pappagallo M, Dal Maso L, Serraino D, Rezza G, Suligoi B: [AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era]. Epidemiol Prev; 2009 Jul-Oct;33(4-5):184-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era].
  • [Transliterated title] AIDS e tossicodipendenza: determinanti della sopravvivenza nell'era delle terapie antiretrovirali altamente efficaci.
  • OBJECTIVES: to estimate survival, after AIDS diagnosis, in people who got infected with HIV through injecting drug use (IDUs), to identify among variables collected at AIDS diagnosis those which were associated to prognosis and to assess the frequency of morbid conditions at death.
  • SETTING AND PARTICIPANTS: 4,040 IDUs diagnosed with AIDS in Italy between 1999 and 2005.
  • RESULTS: the 2-year and 5-year survival probabilities after AIDS diagnosis of IDUs were 72% and 60%, respectively.
  • Elevated risks of death emerged for IDUs with older ages (HR=2.0 95% CI 1.6-2.4 for>45 years old vs.<35 years old), lower education (HR=1.4 95% CI 1.2-1.7 for elementary school vs. high school/university), longer time span between first HIV positive test and AIDS diagnosis (HR=1.6 95% CI 1.4-1.9 for > 6 months vs. < 6 months), and lower CD4 cell count at diagnosis (HR=1.5 95% CI 1.3-1.7 for <50 cells/mm3 vs. > 200 cells/mm3).
  • Compared to Pneumocystis carinii pneumonia, non-Hodgkin lymphomas were the worst prognostic factors, particularly primary brain lymphoma (HR=7.2, 95% CI 4.4-11.8).
  • 52% of cases reported no AIDS-defining illnesses: 64 (4%) violent causes, 94 (6%) cancers, and 656 (42%) only non neoplastic illnesses, among which 415 (27%) liver diseases.
  • CONCLUSION: the results of this population-based study showed that, in the highly active antiretroviral therapy era, survival of IDUs with AIDS was still lower compared to that of HIV sexual transmission groups.
  • The presence at death, in 52% of cases, of non AIDS-defining illnesses indicates the important role on mortality of co-morbidities, including liver diseases and violent causes.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / mortality. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Substance Abuse, Intravenous / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / mortality. Age Factors. Comorbidity. Death Certificates. Educational Status. Equipment Contamination. HIV Infections / transmission. Homicide / statistics & numerical data. Humans. Italy / epidemiology. Kaplan-Meier Estimate. Liver Diseases / mortality. Lymphoma, AIDS-Related / mortality. Medical Record Linkage. Needles. Proportional Hazards Models. Registries. Retrospective Studies. Risk. Sexual Behavior

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124634.001).
  • [ISSN] 1120-9763
  • [Journal-full-title] Epidemiologia e prevenzione
  • [ISO-abbreviation] Epidemiol Prev
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


2. Singer EJ, Valdes-Sueiras M, Commins D, Levine A: Neurologic presentations of AIDS. Neurol Clin; 2010 Feb;28(1):253-75
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurologic presentations of AIDS.
  • The human immunodeficiency virus (HIV), the cause of AIDS, has infected an estimated 33 million individuals worldwide.
  • HIV is associated with immunodeficiency, neoplasia, and neurologic disease.
  • This article reviews the HIV-associated neurologic syndromes, which can be classified as primary HIV neurologic disease (in which HIV is both necessary and sufficient to cause the illness), secondary or opportunistic neurologic disease (in which HIV interacts with other pathogens, resulting in opportunistic infections and tumors), and treatment-related neurologic disease (such as immune reconstitution inflammatory syndrome).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. HIV-1. Nervous System Diseases / etiology
  • [MeSH-minor] AIDS Dementia Complex / pathology. AIDS Dementia Complex / therapy. AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / pathology. AIDS-Related Opportunistic Infections / therapy. Brain / pathology. Humans

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurovirol. 2005 Apr;11(2):180-9 [16036796.001]
  • [Cites] J Infect. 2005 Aug;51(2):165-71 [15961162.001]
  • [Cites] Clin Rev Allergy Immunol. 2005 Dec;29(3):271-9 [16391402.001]
  • [Cites] Clin Infect Dis. 2006 Feb 15;42(4):e21-5 [16421782.001]
  • [Cites] N Engl J Med. 2006 Mar 2;354(9):924-33 [16510746.001]
  • [Cites] J Neurosci. 2006 Mar 29;26(13):3396-403 [16571746.001]
  • [Cites] Clin Infect Dis. 2006 Jun 1;42(11):1639-46 [16652323.001]
  • [Cites] Clin Infect Dis. 2006 Jul 1;43(1):79-89 [16758422.001]
  • [Cites] Curr HIV Res. 2006 Jul;4(3):307-18 [16842083.001]
  • [Cites] Am J Psychiatry. 2006 Aug;163(8):1349-54; quiz 1480 [16877646.001]
  • [Cites] Neurology. 2006 Aug 8;67(3):383-8 [16894096.001]
  • [Cites] J Virol. 2006 Sep;80(18):8929-39 [16940505.001]
  • [Cites] J Neurovirol. 2006 Aug;12(4):328-31 [16966223.001]
  • [Cites] Nat Clin Pract Neurol. 2006 Oct;2(10):557-65 [16990829.001]
  • [Cites] Clin Infect Dis. 2006 Nov 1;43(9):1143-51 [17029132.001]
  • [Cites] AIDS. 2006 Nov 14;20(17):2183-91 [17086058.001]
  • [Cites] Arq Neuropsiquiatr. 2006 Sep;64(3A):606-8 [17119803.001]
  • [Cites] J Neurovirol. 2003;9 Suppl 1:25-31 [12709868.001]
  • [Cites] Neurology. 2003 May 13;60(9):1508-14 [12743240.001]
  • [Cites] J Neurovirol. 2003 Jun;9(3):411-9 [12775425.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1787-93 [12891064.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Sep;83(18):7089-93 [3018755.001]
  • [Cites] J Neuropathol Exp Neurol. 1986 Nov;45(6):635-46 [3021914.001]
  • [Cites] Scand J Infect Dis. 1986;18(6):591-2 [3468607.001]
  • [Cites] Hum Pathol. 1987 Mar;18(3):289-97 [3028930.001]
  • [Cites] Ann Intern Med. 1987 May;106(5):692-5 [3646001.001]
  • [Cites] Am J Med. 1987 Nov;83(5):813-6 [3674088.001]
  • [Cites] Neurology. 1988 Jan;38(1):9-14 [3422110.001]
  • [Cites] AIDS. 1987 May;1(1):35-8 [3122787.001]
  • [Cites] Ann Neurol. 1987 Dec;22(6):700-6 [3501695.001]
  • [Cites] J Infect Dis. 1988 Mar;157(3):508-14 [2830343.001]
  • [Cites] Ann Neurol. 1988;23 Suppl:S54-7 [3279904.001]
  • [Cites] Ann Neurol. 1988;23 Suppl:S88-91 [2831807.001]
  • [Cites] Neurology. 1988 May;38(5):794-6 [2834669.001]
  • [Cites] AIDS. 1988 Apr;2(2):81-8 [3132951.001]
  • [Cites] Ann Neurol. 1988 May;23(5):485-92 [2839106.001]
  • [Cites] Sex Transm Dis. 1988 Apr-Jun;15(2):85-7 [2840745.001]
  • [Cites] N Engl J Med. 1988 Dec 15;319(24):1573-8 [3059187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(9):3337-41 [2717618.001]
  • [Cites] Neurology. 1989 Jul;39(7):892-6 [2739916.001]
  • [Cites] Ann Intern Med. 1990 Aug 1;113(3):183-7 [2197908.001]
  • [Cites] Infect Immun. 1990 Sep;58(9):2919-22 [2117574.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3(12):1155-8 [2173744.001]
  • [Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]
  • [Cites] Clin Infect Dis. 1992 Aug;15(2):211-22 [1520757.001]
  • [Cites] Neurology. 1993 Feb;43(2):358-62 [8382349.001]
  • [Cites] Radiology. 1993 Apr;187(1):233-40 [8451420.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10948-65 [10594076.001]
  • [Cites] Clin Infect Dis. 2000 Jan;30(1):47-54 [10619732.001]
  • [Cites] Clin Infect Dis. 2000 Jan;30(1):95-9 [10619739.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):267-8 [10636172.001]
  • [Cites] AIDS. 2000 Feb 18;14(3):273-8 [10716503.001]
  • [Cites] Neurology. 2000 Mar 14;54(5):1080-8 [10720278.001]
  • [Cites] J Neurol. 2000 Feb;247(2):134-8 [10751117.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1477-82 [10751261.001]
  • [Cites] J Int Neuropsychol Soc. 2000 Mar;6(3):336-47 [10824505.001]
  • [Cites] Neurologia. 2000 Apr;15(4):164-71 [10846884.001]
  • [Cites] Drugs. 2000 Jun;59(6):1251-60 [10882161.001]
  • [Cites] Neurology. 2000 Aug 8;55(3):440-2 [10932285.001]
  • [Cites] Neurology. 2000 Aug 8;55(3):456 [10932295.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):17-23 [15085359.001]
  • [Cites] Herpes. 2004 Jun;11 Suppl 2:95A-104A [15319096.001]
  • [Cites] AIDS. 2004 Jun 18;18(9):1241-50 [15362656.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1270-5 [15477550.001]
  • [Cites] J Neurol. 2004 Oct;251(10):1260-6 [15503108.001]
  • [Cites] J Infect Dis. 1973 Apr;127(4):467-70 [4571704.001]
  • [Cites] Ann Neurol. 1981;9 Suppl:20-7 [6261678.001]
  • [Cites] Ann Neurol. 1983 Oct;14(4):403-18 [6314874.001]
  • [Cites] J Neurosurg. 1985 Apr;62(4):475-95 [2983051.001]
  • [Cites] N Engl J Med. 1985 Apr 4;312(14):874-9 [3974673.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63 [19731418.001]
  • [Cites] J Clin Exp Neuropsychol. 2008 Oct;30(7):836-43 [18608693.001]
  • [Cites] Ann Neurol. 1993 Apr;33(4):343-9 [8489204.001]
  • [Cites] J Neurol. 1993;240(4):223-31 [8388434.001]
  • [Cites] AIDS. 1993 May;7(5):669-75 [8318174.001]
  • [Cites] Neurology. 1993 Nov;43(11):2245-52 [8232937.001]
  • [Cites] West J Med. 1993 Nov;159(5):604-5 [8279169.001]
  • [Cites] Ann Neurol. 1994 Jan;35(1):53-8 [8285593.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Jan;53(1):86-94 [8301324.001]
  • [Cites] Neurology. 1994 Jul;44(7):1264-70 [8035927.001]
  • [Cites] Neurology. 1994 Nov;44(11):2159-64 [7969977.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Nov;15(10):1885-94 [7863938.001]
  • [Cites] Ann Intern Med. 1995 Oct 15;123(8):594-8 [7677300.001]
  • [Cites] Arch Intern Med. 2001 Feb 12;161(3):411-20 [11176767.001]
  • [Cites] Arch Neurol. 2001 Mar;58(3):473-9 [11255452.001]
  • [Cites] J Peripher Nerv Syst. 2001 Mar;6(1):8-13 [11293807.001]
  • [Cites] J Neuroimmunol. 2001 May 1;116(1):29-39 [11311327.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2001 Spring;13(2):248-54 [11449032.001]
  • [Cites] Arch Gen Psychiatry. 2001 Aug;58(8):721-8 [11483137.001]
  • [Cites] Ann Trop Med Parasitol. 2001 Sep;95(6):587-93 [11672464.001]
  • [Cites] Neurology. 2002 Feb 12;58(3):479-81 [11839857.001]
  • [Cites] Neurology. 2002 Mar 12;58(5):730-5 [11889235.001]
  • [Cites] Ophthalmic Res. 2002 Mar-Apr;34(2):77-82 [11914609.001]
  • [Cites] J Int Neuropsychol Soc. 2002 Mar;8(3):410-24 [11939699.001]
  • [Cites] Neuroradiology. 1997 Dec;39(12):865-9 [9457712.001]
  • [Cites] J Neurovirol. 1998 Feb;4(1):59-68 [9531012.001]
  • [Cites] N Engl J Med. 1998 May 7;338(19):1345-51 [9571254.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):23-8 [9667556.001]
  • [Cites] AIDS Patient Care STDS. 1998 Jun;12(6):457-61 [11361993.001]
  • [Cites] JAMA. 1998 Nov 11;280(18):1590-5 [9820261.001]
  • [Cites] Neurology. 1998 Dec;51(6):1682-8 [9855523.001]
  • [Cites] Am J Ophthalmol. 1998 Dec;126(6):817-22 [9860006.001]
  • [Cites] Clin Infect Dis. 2007 Mar 15;44(6):e57-61 [17304442.001]
  • [Cites] J Int Neuropsychol Soc. 2007 May;13(3):549-54 [17445305.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):689-700 [17492932.001]
  • [Cites] PLoS One. 2007;2(6):e551 [17653259.001]
  • [Cites] Brain. 2007 Aug;130(Pt 8):2011-23 [17616550.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2007 Summer;19(3):283-92 [17827413.001]
  • [Cites] J HIV Ther. 2007 Sep;12(3):62-3 [17962793.001]
  • [Cites] Neurology. 2007 Oct 30;69(18):1789-99 [17914061.001]
  • [Cites] AIDS. 2007 Oct 18;21(16):2119-29 [18090038.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Sep;20(8):1412-6 [10512221.001]
  • [Cites] Brain. 1958 Mar;81(1):93-111 [13523006.001]
  • [Cites] J Med Virol. 2005 Jan;75(1):59-69 [15543571.001]
  • [Cites] J Neuroimmunol. 2004 Dec;157(1-2):3-10 [15579274.001]
  • [Cites] Neurology. 2004 Dec 14;63(11):2084-90 [15596754.001]
  • [Cites] Clin Infect Dis. 2005 Jan 1;40(1):148-57 [15614705.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):207-15 [15621803.001]
  • [Cites] J Microbiol Immunol Infect. 2005 Feb;38(1):65-8 [15692630.001]
  • [Cites] AIDS. 2005 Mar 4;19(4):399-406 [15750393.001]
  • [Cites] CNS Drugs. 2005;19(4):325-34 [15813646.001]
  • [Cites] Acta Neuropathol. 2005 Apr;109(4):449-55 [15739098.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2005 Spring;17(2):167-71 [15939969.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):426-9 [16010165.001]
  • [Cites] Clin Infect Dis. 1995 Oct;21 Suppl 2:S196-201 [8845453.001]
  • [Cites] J Nucl Med. 1996 Jul;37(7):1133-41 [8965184.001]
  • [Cites] J Neurol Sci. 1996 Jun;138(1-2):134-44 [8791251.001]
  • [Cites] Ann Intern Med. 1996 Oct 1;125(7):577-87 [8815757.001]
  • [Cites] Neurology. 1996 Nov;47(5):1254-9 [8909439.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Nov;61(5):456-60 [8937337.001]
  • [Cites] J Clin Microbiol. 1996 Dec;34(12):2929-32 [8940424.001]
  • [Cites] Clin Infect Dis. 1997 Feb;24(2):131-4 [9114135.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1997 Spring;9(2):277-9 [9144109.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):250-4 [9207375.001]
  • [Cites] AIDS. 1997 Nov 15;11(14):1731-8 [9386808.001]
  • [Cites] Neurology. 1999 Feb;52(3):623-5 [10025799.001]
  • [Cites] J Radiol. 1999 Feb;80(2):99-107 [10209706.001]
  • [Cites] Neurology. 1999 May 12;52(8):1640-7 [10331692.001]
  • [Cites] AIDS. 1999 Jul 9;13(10):1249-53 [10416530.001]
  • [Cites] Neuroimage. 2007 Jan 1;34(1):44-60 [17035049.001]
  • [Cites] Neurology. 2007 Feb 13;68(7):515-21 [17296917.001]
  • [Cites] J HIV Ther. 2008 Sep;13(3):55-8 [19039299.001]
  • [Cites] J Infect Dis. 2009 Jan 1;199(1):77-83 [19007313.001]
  • [Cites] J Microbiol Immunol Infect. 2008 Oct;41(5):386-92 [19122919.001]
  • [Cites] Neuropsychopharmacology. 2009 Feb;34(3):672-80 [18688212.001]
  • [Cites] J Med Microbiol. 2009 Feb;58(Pt 2):253-5 [19141745.001]
  • [Cites] HIV Clin Trials. 2008 Nov-Dec;9(6):434-9 [19203909.001]
  • [Cites] AIDS. 2002 May 3;16(7):1019-29 [11953468.001]
  • [Cites] Arch Neurol. 2002 Jun;59(6):923-8 [12056927.001]
  • [Cites] AIDS. 2002 Jul 26;16(11):1562 [12131198.001]
  • [Cites] J Virol. 2002 Aug;76(16):7923-31 [12133996.001]
  • [Cites] AIDS. 2002 Sep 6;16(13):1791-7 [12218391.001]
  • [Cites] Curr Opin Neurol. 2002 Oct;15(5):633-8 [12352008.001]
  • [Cites] J Neurovirol. 2002 Oct;8(5):432-8 [12402169.001]
  • [Cites] J Neurovirol. 2002 Dec;8 Suppl 2:33-41 [12491149.001]
  • [Cites] J Neurovirol. 2002 Dec;8 Suppl 2:122-8 [12491163.001]
  • [Cites] Semin Neurol. 2002 Jun;22(2):133-42 [12524558.001]
  • [Cites] Acta Radiol. 2003 Mar;44(2):206-12 [12694109.001]
  • [Cites] Arch Neurol. 2008 Jan;65(1):65-70 [18195140.001]
  • [Cites] Pharmacogenomics J. 2008 Feb;8(1):71-7 [17684475.001]
  • [Cites] PLoS One. 2008;3(4):e1950 [18414656.001]
  • [Cites] Antivir Ther. 2008;13(2):289-95 [18505180.001]
  • [Cites] Neurology. 2008 Jun 10;70(24):2305-13 [18541884.001]
  • [Cites] Int J Infect Dis. 2008 Jul;12(4):442-4 [18082439.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(3):CD006496 [18646159.001]
  • [Cites] J Int Neuropsychol Soc. 2008 Sep;14(5):725-33 [18764968.001]
  • [Cites] AIDS. 2003 Sep 26;17(14):2145-6 [14502028.001]
  • [Cites] Clin Infect Dis. 2003 Oct 15;37(8):1107-11 [14523776.001]
  • [Cites] J Neuropathol Exp Neurol. 1986 Mar;45(2):127-39 [3005516.001]
  • [Cites] N Engl J Med. 1986 Apr 3;314(14):874-9 [3005862.001]
  • [Cites] Ann Neurol. 1986 Jun;19(6):517-24 [3729308.001]
  • [Cites] Ann Neurol. 1986 Jun;19(6):525-35 [3014994.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] Neurology. 2009 Apr 28;72(17):1465-72 [19398702.001]
  • [Cites] Top HIV Med. 2009 Apr-May;17(2):46-56 [19401607.001]
  • [Cites] J Neuroimmune Pharmacol. 2009 Jun;4(2):163-74 [19067177.001]
  • [Cites] Neuropsychol Rev. 2009 Jun;19(2):152-68 [19462243.001]
  • [Cites] AIDS. 2009 Jul 17;23(11):1359-66 [19424052.001]
  • [Cites] Neurology. 2009 Jul 28;73(4):321-2 [19636053.001]
  • [Cites] Neurology. 2009 Aug 4;73(5):401-3 [19652146.001]
  • [Cites] J Neuroimaging. 2009 Apr;19(2):169-73 [19705517.001]
  • [Cites] Biochemistry. 2003 Dec 23;42(50):14711-9 [14674745.001]
  • [Cites] Eur J Neurol. 2004 Feb;11(2):97-102 [14748769.001]
  • [Cites] Neurology. 2004 Feb 24;62(4):544-7 [14981168.001]
  • [Cites] Neurology. 2004 Feb 24;62(4):548-55 [14981169.001]
  • [Cites] AIDS. 2004 Jan 1;18 Suppl 1:S61-7 [15075499.001]
  • [Cites] AIDS. 2004 Jan 1;18 Suppl 1:S75-8 [15075501.001]
  • [Cites] Eur J Neurol. 2004 May;11(5):297-304 [15142222.001]
  • (PMID = 19932385.001).
  • [ISSN] 1557-9875
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / U01MH083500; United States / NIDA NIH HHS / DA / R03 DA026099; United States / NIMH NIH HHS / MH / U24 MH100929; United States / NIMH NIH HHS / MH / U01 MH083500; United States / NIMH NIH HHS / MH / U01 MH083500-02; United States / NINDS NIH HHS / NS / R24 NS038841-10; United States / NINDS NIH HHS / NS / R24 NS038841; United States / NIDA NIH HHS / DA / R03DA026099; United States / NINDS NIH HHS / NS / NS38841
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 191
  • [Other-IDs] NLM/ NIHMS166363; NLM/ PMC2806427
  •  go-up   go-down


3. Goldstein MA, Naidich TP, Silverman ME: Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS.
  • Accurately distinguishing between cerebral toxoplasmosis and primary central nervous system lymphoma (PCNSL), still the most common secondary CNS mass lesion complications of AIDS, has long represented a diagnostic challenge in those with HIV.
  • A young adult male with AIDS presented with evolving ophthalmoplegias, Parinaud's syndrome and gait dysfunction.
  • MRI with gadolinium contrast revealed a brainstem lesion failing to enhance on initially obtained post-contrast images yet prominently enhancing on images acquired endmost within the same scanning session.
  • While the definitive diagnosis of PCNSL generally requires brain biopsy, different MRI contrast-enhancement time courses of PCNSL versus toxoplasmosis (PCNSL tends to peak-enhance sooner than toxoplasmosis) can provide differential diagnostic insight.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2003 Apr;24(4):554-5 [12695179.001]
  • [Cites] Neurology. 1998 Jan;50(1):21-6 [9443452.001]
  • (PMID = 21686485.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027744
  •  go-up   go-down


Advertisement
4. Fallo A, De Matteo E, Preciado MV, Cerqueiro MC, Escoms S, Chabay P, López E: Epstein-Barr virus associated with primary CNS lymphoma and disseminated BCG infection in a child with AIDS. Int J Infect Dis; 2005 Mar;9(2):96-103
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus associated with primary CNS lymphoma and disseminated BCG infection in a child with AIDS.
  • BACKGROUND: AIDS patients are at increased risk of developing concurrent infections with viral, parasitic, fungal or mycobacterial organisms.
  • They can present constitutional symptoms of fever and weight loss, either due to infections or an underlying lymphoma which may coexist.
  • CASE REPORT: A child with HIV-AIDS and mild encephalopathy is reported, who during the course of a confirmed disseminated mycobacterial disease developed neurological impairment.
  • Post-mortem examination revealed disseminated BCG infection and Epstein-Barr associated primary CNS lymphoma.
  • Only isolated cases of primary CNS lymphoma occurring in HIV-infected children have been reported, and a striking association with EBV infection has been demonstrated.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. BCG Vaccine / adverse effects. Brain Neoplasms / etiology. Burkitt Lymphoma / etiology. Tuberculosis / etiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections. Child, Preschool. Fatal Outcome. Female. Humans


5. Haldorsen IS, Kråkenes J, Goplen AK, Dunlop O, Mella O, Espeland A: AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989-2003. BMC Cancer; 2008;8:225
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989-2003.
  • BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a frequent complication in acquired immunodeficiency syndrome (AIDS).
  • The objective of this survey was to investigate incidence, clinical features, radiological findings, histologic diagnosis, treatment and outcome for all patients with histologically verified AIDS-related PCNSL diagnosed in Norway in 1989-2003.
  • METHODS: We identified the patients by chart review of all cases recorded as PCNSL in The Norwegian Cancer Registry (by law recording all cases of cancer in Norway) and all cases recorded as AIDS-related PCNSL in the autopsy registry at a hospital having 67% autopsy rate and treating 59% of AIDS patients in Norway, from 1989 to 2003.
  • We used person-time techniques to calculate incidence rates of PCNSL among AIDS patients based on recordings on AIDS at the Norwegian Surveillance System for Communicable Diseases (by law recording all cases of AIDS in Norway).
  • RESULTS: Twenty-nine patients had histologically confirmed, newly diagnosed AIDS-related PCNSL in Norway from 1989-2003.
  • Only 2 patients had this diagnosis established while alive.
  • AIDS patients had 5.5% lifetime risk of PCNSL.
  • CONCLUSION: This is the first national survey to confirm decreasing incidence of AIDS-related PCNSL.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / epidemiology. Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / epidemiology. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adult. Brain / pathology. Female. Humans. Incidence. Male. Middle Aged. Norway. Registries. Risk. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2003 Aug 15;17(12):1787-93 [12891064.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2627-36 [15197806.001]
  • [Cites] HIV Med. 2004 Sep;5(5):377-84 [15369514.001]
  • [Cites] AIDS. 1995 Nov;9(11):1243-50 [8561977.001]
  • [Cites] J Natl Cancer Inst. 1996 May 15;88(10):675-9 [8627644.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 1;14(4):351-4 [9111477.001]
  • [Cites] Neuroimaging Clin N Am. 1997 May;7(2):281-96 [9113691.001]
  • [Cites] AIDS. 1998 May 28;12(8):952-4 [9631151.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):365-71 [9704942.001]
  • [Cites] Crit Rev Oncog. 1998;9(3-4):199-208 [10201628.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):207-15 [15621803.001]
  • [Cites] HIV Med. 2005 Mar;6(2):66-78 [15807712.001]
  • [Cites] MMWR Recomm Rep. 2004 Dec 17;53(RR-15):1-112 [15841069.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):665-87, vi-vii [16083829.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Neurovirol. 2005;11 Suppl 3:38-44 [16540454.001]
  • [Cites] Cancer. 2007 Oct 15;110(8):1803-14 [17721992.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):269-76 [10563433.001]
  • [Cites] AIDS. 2000 Jan 7;14(1):69-74 [10714569.001]
  • [Cites] Neurology. 2000 Oct 24;55(8):1194-200 [11071499.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):451-8 [11141245.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Eur J Epidemiol. 2001;17(5):479-89 [11855582.001]
  • [Cites] Front Biosci. 2004 Jan 1;9:632-46 [14766397.001]
  • (PMID = 18684320.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2525658
  •  go-up   go-down


6. Latta S, Myint ZW, Jallad B, Hamdi T, Alhosaini MN, Kumar DV, Kheir F: Primary central nervous system T-cell lymphoma in aids patients: case report and literature review. Curr Oncol; 2010 Oct;17(5):63-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system T-cell lymphoma in aids patients: case report and literature review.
  • According to the published data, most primary central nervous system lymphomas (PCNSLs) are B-cell lymphomas; primary T-cell lymphomas are rare.
  • In a search of the MEDLINE database, we found only 6 cases of primary T-cell PCNSL.
  • Here, we present the case of a 43-year-old man with AIDS, not on highly active antiretroviral therapy, who presented with focal neurologic symptoms and was found on magnetic resonance imaging to have multiple brain lesions.
  • A biopsy showed T-cell lymphoma, and the patient was subsequently treated with whole-brain radiation, to marked clinical response.
  • Reported cases from the literature of primary T-cell PCNSL in AIDS patients are summarized in this review.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20975881.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2949374
  • [Keywords] NOTNLM ; Primary cns lymphoma / T cells / aids / non-Hodgkin lymphoma
  •  go-up   go-down


7. Fellner MD, Durand K, Correa RM, Redini L, Yampolsky C, Colobraro A, Sevlever G, Teyssié AR, Benetucci J, Picconi MA: Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma. Int J Infect Dis; 2007 Mar;11(2):172-8
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma.
  • OBJECTIVE: To analyze Epstein-Barr virus (EBV) load at different HIV infection stages and its relation with brain lymphoma.
  • DESIGN: A cross-sectional study was conducted on 172 HIV-infected individuals: 62 asymptomatic HIV carriers (group A), 30 HIV progressors (group B), 73 AIDS patients (group C), seven AIDS patients with brain lymphoma (group C-BL); and 26 blood donors (group BD) as healthy carriers.
  • In all HIV-infected patients, plasma-EBV load was lower than, or similar to, PBMC-EBV load, unlike 2/7 HIV-positive brain lymphoma patients.
  • Circulating EBV is mainly cell-associated in the HIV-infected population.
  • Neither PBMC-EBV nor plasma-EBV loads would be useful to diagnose brain lymphoma in AIDS patients.
  • [MeSH-major] Brain Neoplasms / virology. HIV Infections / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931088.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


8. Ilniczky S, Debreczeni R, Kovács T, Várkonyi V, Barsi P, Szirmai I: [Aids-related toxoplasma-encephalitis presenting with acute psychotic episode]. Ideggyogy Sz; 2006 Jul 20;59(7-8):289-93
MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aids-related toxoplasma-encephalitis presenting with acute psychotic episode].
  • [Transliterated title] Akut psychosis mint az AIDS-hez társuló toxoplasma-encephalitis elso tünete.
  • The most frequent neurological manifestations of the Acquired Immunodeficiency Syndrome-(AIDS) are Cerebral Toxoplasmosis, Primary Central Nervous System Lymphoma (PCNSL), Progressive Multifocal Leukoencephalopathy (PML) and AIDS-encephalitis (AIDS-dementia complex, multinucleated giant cell encephalitis, HIV-encephalopathy).
  • Rarely the disease presents as a neuropsychiatric illness in an undiagnosed AIDS patient, delaying a proper diagnosis.
  • We present the case of a 34 years old patient treated for AIDS-related Toxoplasma-encephalitis in our department.
  • The diagnosis was established by serology, imaging methods and histopathological investigation.
  • After presenting the medical history and results of autopsy studies of the patient we discuss the problems of the differential diagnosis, especially regarding the findings of the imaging methods.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / parasitology. Brain / parasitology. Brain / pathology. HIV Seropositivity. Homosexuality, Male. Toxoplasma / isolation & purification. Toxoplasmosis, Cerebral / diagnosis
  • [MeSH-minor] Adult. Animals. Antibodies, Viral / blood. Atrophy. Autopsy. Epstein-Barr Virus Infections / diagnosis. Fatal Outcome. Herpesvirus 4, Human / isolation & purification. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076307.001).
  • [ISSN] 0019-1442
  • [Journal-full-title] Ideggyógyászati szemle
  • [ISO-abbreviation] Ideggyogy Sz
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


9. Nagai H, Odawara T, Ajisawa A, Tanuma J, Hagiwara S, Watanabe T, Uehira T, Uchiumi H, Yotsumoto M, Miyakawa T, Watanabe A, Kambe T, Konishi M, Saito S, Takahama S, Tateyama M, Okada S: Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol; 2010 Jun;84(6):499-505
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era.
  • Primary central nervous system lymphoma (PCNSL) related to acquired immunodeficiency syndrome (AIDS) is a lethal disorder, but the recent application of highly active antiretroviral therapy (HAART) has significantly improved prognosis.
  • This retrospective cohort study of AIDS-related PCNSL examined the actual clinical outcomes and prognostic variables affecting overall survival (OS) in the HAART era.
  • Twenty-three newly diagnosed AIDS-related PCNSL at 12 regional centre hospitals for HIV/AIDS in Japan between 2002 and 2008 were consecutively enrolled.
  • Whole brain radiation therapy (WBRT) had an independent positive impact on survival (WBRT >or=30 Gy vs. others, P = 0.02).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Lymphoma, AIDS-Related / radiotherapy

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Haematol. 2010 Sep;85(3):277. Tanuma, Junko [added]
  • (PMID = 20132301.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Castro-Rebollo M, Vleming EN, Drake-Rodríguez P, Benítez-Herreros J, Pérez-Rico C: [Primary cerebral lymphoma diagnosed by the ophthalmologist]. Arch Soc Esp Oftalmol; 2010 Jan;85(1):35-7
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cerebral lymphoma diagnosed by the ophthalmologist].
  • [Transliterated title] Diagnóstico de linfoma cerebral primario por el oftalmólogo.
  • The biopsy confirmed the diagnosis of lymphoid neoplasm.
  • DISCUSSION: Primary lymphoma is the most common malignancy of the central nervous system (CNS) in AIDS patients, although highly active antiretroviral therapy has reduced its incidence.
  • The ophthalmologist plays an essential role in the diagnosis of CNS neoplasm.
  • [MeSH-major] Brain Neoplasms / diagnosis. Lymphoma / diagnosis. Parietal Lobe

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20566168.001).
  • [ISSN] 1989-7286
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


11. Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr, AIDS Associated Malignancies Clinical Trials Consortium: Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma; 2006 Mar;6(5):399-402
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019.
  • PURPOSE: A consistent association with Epstein-Barr Virus (EBV) distinguishes acquired immunodeficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL) from that which occurs in the general population.
  • Recent descriptions of long-term remissions in patients with posttransplantation EBV-associated PCNSL who received EBV-specific therapy suggest some antitumor effect is anti-EBV mediated.
  • PATIENTS AND METHODS: We enrolled 4 patients with AIDS-related PCNSL into a novel antiviral and immunomodulatory protocol.
  • All 6 patients had advanced-stage AIDS as reflected by a CD4+ T-lymphocyte cell count of < 50/microL and a detectable human immunodeficiency virus (HIV)-1 viral RNA load (median copies, 135,000/mL; range, 2170-360,000/mL).
  • CONCLUSION: We conclude that for patients with AIDS and PCNSL, treatments with dual efficacy against HIV and EBV merit further investigation.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Interleukins / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Positron-Emission Tomography. Prospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome


12. Stern JI, Raizer JJ: Primary central nervous system lymphoma. Expert Rev Neurother; 2005 Nov;5(6 Suppl):S63-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma.
  • Primary central nervous system lymphoma is a stage 1E non-Hodgkin's lymphoma confined to the nervous system.
  • It is seen in immunocompetent and immunodeficient populations, the latter group associated with the Epstein-Barr virus.
  • Primary central nervous system lymphoma can affect the brain, leptomeninges, spinal cord or eyes.
  • The institution of high-dose methotrexate-based regimens and whole-brain radiation therapy has significantly increased survival, but neurotoxicity is high in patients over 60 years of age.
  • Recent investigations include the use of rituximab (immunotherapy) and stem-cell transplantation, as well as regimens without whole-brain radiation therapy in the elderly.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / therapy. Lymphoma / pathology. Lymphoma / therapy
  • [MeSH-minor] Diagnostic Imaging / methods. Drug Therapy / methods. Expert Testimony. Humans. Lymphoma, AIDS-Related. Prognosis. Radiotherapy / methods. Salvage Therapy / methods. Stem Cell Transplantation / methods. Steroids / therapeutic use

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Expert Rev Neurother. 2005 Nov;5(6 Suppl):1-2 [16274264.001]
  • (PMID = 16274272.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Steroids
  • [Number-of-references] 76
  •  go-up   go-down


13. Corti M, Metta H, Villafañe MF, Yampolsky C, Schtirbu R, Sevlever G, Garrido D: [Stereotactic brain biopsy in the diagnosis of focal brain lesions in AIDS]. Medicina (B Aires); 2008;68(4):285-90
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stereotactic brain biopsy in the diagnosis of focal brain lesions in AIDS].
  • [Transliterated title] La biopsia estereotáctica en el diagnóstico de las lesiones cerebrales focales en sida.
  • Focal brain lesions are frequent complications among HIV/AIDS patients.
  • Between January 1999 and May 2007, 83 procedures of stereotactic brain biopsies in HIV/AIDS patients with focal cerebral lesions were carried out.
  • The inclusion criteria were lack of response to current diagnostic and therapeutic guidelines for brain lesions.
  • Forty one patient images demonstrated multiple brain lesions.
  • Progressive multifocal leucoencephalopathy (PML) was the most frequent diagnosis (29%), followed by primary central nervous system lymphoma (PCNSL) (23%), and toxoplasmosis (15.7%).
  • Statistically significant association was observed between histopathological diagnosis and lesion location and between those and peripheral ring enhancement images.
  • In conclusion, the stereotactic brain biopsy ordered early during the patient's evolution showed a good performance in order to achieve a prompt and accurate diagnosis and to guide the therapeutic scheme in these AIDS patients with focal brain lesions.
  • [MeSH-major] AIDS-Related Opportunistic Infections / pathology. Acquired Immunodeficiency Syndrome / pathology. Biopsy / methods. Brain / pathology. Brain Diseases / pathology. Central Nervous System Viral Diseases / pathology


14. Camilleri-Broët S, Raphaël M: [Physiopathogenic aspects of HIV-associated primary brain lymphomas]. Rev Neurol (Paris); 2006 Jan;162(1):57-61
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Physiopathogenic aspects of HIV-associated primary brain lymphomas].
  • [Transliterated title] Les lymphomes cérébraux primitifs associés au SIDA: aspects physiopathogéniques.
  • HIV-associated Primary brain lymphomas (PBLs) are usually diffuse, large B-cell lymphomas (DLBCLs).
  • In contrast to those occurring in immunocompetent patients, nearly all HIV-associated PBLs are associated with Epstein-Barr virus (EBV).
  • Since viral latency proteins are target antigens for anti-viral cytotoxic T lymphocytes, the double immunodeficiency (HIV infection, central nervous system microenvironment) favors the expression of viral latency proteins (LMP-1, EBNA2).
  • [MeSH-major] Brain Neoplasms / physiopathology. Lymphoma, AIDS-Related / physiopathology
  • [MeSH-minor] B-Lymphocytes / pathology. B-Lymphocytes / virology. Biopsy. Brain / pathology. Brain / virology. Cerebrospinal Fluid / immunology. Epstein-Barr Virus Infections / complications. HIV / physiology. Herpesvirus 4, Human / isolation & purification. Humans. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / physiopathology. Lymphoma, Large B-Cell, Diffuse / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446623.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 25
  •  go-up   go-down


15. Haldorsen IS, Espeland A, Larsen JL, Mella O: Diagnostic delay in primary central nervous system lymphoma. Acta Oncol; 2005;44(7):728-34
Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic delay in primary central nervous system lymphoma.
  • This study investigates delay in diagnosing primary central nervous system lymphoma (PCNSL), which has a variable clinical and radiological presentation.
  • Early diagnosis and treatment may improve survival and cause less sequela in PCNSL.
  • The time from initial symptom to final morphological diagnosis of PCNSL had a median (mean, range) of 70 (106, 22-330) days in 16 AIDS patients and 75 (157, 8-1285) days in 58 non-AIDS patients.
  • Among non-AIDS patients, the time to diagnosis was longer in patients with no tumour in the first neuroimaging report after initial symptom (p = 0.001).
  • Median (mean, range) time from initial symptom to neuroimaging was 14 (25, 1-60) days in AIDS patients and 21 (88, 1-1095) days in non-AIDS patients.
  • In the non-AIDS group, those presenting with personality change or visual disturbance had more delayed imaging than the others.
  • The time from first neuroimaging examination to final diagnosis in non-AIDS patients had a median (mean, range) of 28 (69, 1-845) days, and was longer when no tumour was indicated in the imaging report (p = 0.005) and if first biopsy did not confirm the diagnosis (p = 0.02).
  • All AIDS patients had their diagnosis of PCNSL first established by autopsy.
  • There is a considerable delay in the diagnosis of PCNSL and strategies for earlier diagnosis are thus needed.
  • Physicians should consider early neuroimaging in patients with personality changes or visual disturbance, early renewed imaging in patients with persistent neurological symptoms but no tumour on initial imaging, and early/repeated biopsy of focal brain lesions in both AIDS patients and non-AIDS patients.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurologic Examination. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227164.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


16. Cingolani A, Fratino L, Scoppettuolo G, Antinori A: Changing pattern of primary cerebral lymphoma in the highly active antiretroviral therapy era. J Neurovirol; 2005;11 Suppl 3:38-44
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for cerebral lymphoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing pattern of primary cerebral lymphoma in the highly active antiretroviral therapy era.
  • Before the introduction of highly active antiretroviral therapy (HAART), human immunodeficiency virus (HIV)-related primary central nervous system lymphoma (PCNSL) represented one of the most prevalent causes of focal brain lesions in HIV-infected people.
  • Brain biopsy was the method of choice for the definitive diagnosis, but it was and remains an invasive procedure with morbidity and mortality as well as considerable costs in terms of patients' management and quality of life.
  • The strict association between AIDS-PCNSL and Epstein-Barr virus led to the suggestion that EBV DNA in cerebrospinal spinal fluid (CSF) might serve as a diagnostic marker, reducing the time required for diagnosis and allowing a minimally invasive approach.
  • After the introduction of HAART in clinical practice, a survival benefit has been observed for most persons with acquired immunodeficiency syndrome (AIDS)-associated opportunistic infections and cancers.
  • In particular, for patients with non-Hodgkin lymphoma, a higher likelihood of response to chemotherapy as well as a longer survival has been found as a consequence of the use of combined antiretroviral therapy.
  • Nevertheless, these patients' survival still remains very poor and it could be hypothesized that, other than specific cancer prognostic determinants and severe immunodeficiency, viral pathogenesis as well as EBV-specific immunologic dysfunction may be responsible.
  • [MeSH-major] AIDS-Related Opportunistic Infections / etiology. Antiretroviral Therapy, Highly Active. Brain Neoplasms / etiology. HIV Infections / drug therapy. Lymphoma, AIDS-Related / etiology


17. Schultz CJ, Bovi J: Current management of primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys; 2010 Mar 1;76(3):666-78
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of primary central nervous system lymphoma.
  • Primary central nervous cell lymphoma (PCNSL) is an uncommon neoplasm of the brain, leptomeninges, and rarely the spinal cord.
  • Initially thought to be characteristically associated with congenital, iatrogenic, or acquired immunosuppression, PCNSL is now recognized with increasing frequency in immunocompetent individuals.
  • The role of surgery is limited to establishing diagnosis, as PCNSL is often multifocal with a propensity to involve the subarachnoid space.
  • A whole-brain radiation volume has empirically been used to adequately address the multifocal tumor frequently encountered at the time of PCNSL diagnosis.
  • Despite high rates of response after whole-brain radiotherapy (WBRT), rapid recurrence is common and long-term survival is the exception.
  • Most effective regimens contain high-dose methotrexate and or other agents that are capable of penetrating the blood-brain barrier.
  • Unfortunately, elimination of WBRT is also associated with a higher rate of relapse.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Lymphoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy / methods. Cranial Irradiation / adverse effects. Diagnostic Imaging / methods. Humans. Immunocompetence. Lymphoma, AIDS-Related / therapy. Prognosis. Radiotherapy Planning, Computer-Assisted / methods

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20159361.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 72
  •  go-up   go-down


18. Lolli V, Tampieri D, Melançon D, Delpilar Cortes M: Imaging in primary central nervous system lymphoma. Neuroradiol J; 2010 Dec;23(6):680-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging in primary central nervous system lymphoma.
  • Primary central nervous system (CNS) lymphoma (PCNSL) accounts for approximately 3% of all primary CNS tumors.
  • Congenital or acquired immunodeficiency is the only established risk factor for PCNSL.
  • Rates decreased slightly in the mid-1990s, concordantly with the decreasing rates of AIDS.
  • However, the incidence has been increasing in the elderly immunocompetent population, and this trend seems to be independent of improvements in diagnostic techniques, and of overall trends in the incidence of brain tumors and systemic lymphomas.
  • No changes in the imaging presentation have occurred over the past two decades, apart from lesions now being smaller at diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24148721.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Aboulafia DM, Puswella AL: Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS; 2007 Dec;21(12):900-7
HIV InSite. treatment guidelines - Symptom Management .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment.
  • A brain imaging study showed a right temporal mass, which on biopsy proved to be primary central nervous system lymphoma (PCNSL).
  • He began highly active antiretroviral therapy (HAART) but declined palliative whole-brain radiotherapy (WBRT).
  • For patients who present with PCNSL as their initial AIDS-defining event, stable neurologic findings, and effective HAART options, initial treatment with HAART alone may be possible, reserving WBRT and corticosteroids for those who show signs of impending neurologic demise.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Central Nervous System Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy


20. Algazi AP, Kadoch C, Rubenstein JL: Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics; 2009 Jul;6(3):587-97
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology and treatment of primary central nervous system lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is a rare variant of extranodal non-Hodgkin lymphoma that is restricted in distribution to the brain, leptomeninges, spinal cord, and intraocular compartments.
  • Although PCNSL shares overlapping features with systemic lymphoma, recent studies also reveal a unique pattern of gene and protein expression in PCNSL.
  • Immune system compromise, such as is seen in acquired immune deficiency syndrome (AIDS), is the best established known risk factor for PCNSL.
  • Like other lesions of the brain, meninges, and eye, the presenting symptoms associated with PCNSL typically include focal neurological deficits related to the site of disease or more global consequences of increased intracranial pressure.
  • Diagnosis of PCNSL typically includes gadolinium-enhanced MRI and pathologic tissue analysis, as well as additional studies aimed at excluding concurrent systemic disease.
  • PCNSL typically has a worse overall prognosis than systemic lymphoma.
  • High-dose chemotherapy, particularly with methotrexate-based regimens, is the backbone of therapy for most patients, and chemotherapy is associated with much lower rates of treatment-related morbidity and mortality than whole-brain irradiation.
  • Treatment options for intraocular lymphoma parallel those for PCNSL elsewhere in the brain: systemic chemotherapy, radiation, and local delivery of cytotoxic and immunologically active agents such as anti-CD20 antibody.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / therapy. Lymphoma / physiopathology. Lymphoma / therapy
  • [MeSH-minor] Biomarkers / metabolism. Diagnosis, Differential. Drug Therapy / methods. Eye Neoplasms / epidemiology. Eye Neoplasms / physiopathology. Eye Neoplasms / therapy. Humans. Immunologic Deficiency Syndromes / epidemiology. Immunotherapy / methods. Radiotherapy / methods. Risk Factors. Salvage Therapy / methods. Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19560747.001).
  • [ISSN] 1933-7213
  • [Journal-full-title] Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
  • [ISO-abbreviation] Neurotherapeutics
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 99
  • [Other-IDs] NLM/ NIHMS130545; NLM/ PMC4942275
  •  go-up   go-down


21. Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J: Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst; 2006 Aug 2;98(15):1088-91
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma.
  • From a cohort of 9621 human immunodeficiency virus type 1-infected individuals, we identified 61 patients with primary central nervous system lymphoma (PCL) who had a median survival of 1.3 months.
  • We compared clinicopathologic variables of patients who were treated in the pre-highly active antiretroviral therapy (HAART) and HAART eras and investigated whether exposure to antiretroviral agents with differing cerebrospinal fluid penetrations was associated with risk for PCL.
  • In the HAART era, fewer patients had prior acquired immunodeficiency syndrome-defining illnesses than in the pre-HAART era (64% versus 90%; P = .013), and patients were more likely to have the diagnosis of PCL confirmed histologically or by polymerase chain reaction (77% versus 26%; P<.001).
  • Exposure to specific antiretroviral agents was not associated with risk for PCL.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Brain Neoplasms / prevention & control. Brain Neoplasms / virology. Lymphoma, AIDS-Related / prevention & control

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882946.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


22. Eichler AF, Batchelor TT: Primary central nervous system lymphoma: presentation, diagnosis and staging. Neurosurg Focus; 2006;21(5):E15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: presentation, diagnosis and staging.
  • Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain, spinal cord, leptomeninges, and eyes.
  • The clinical presentation and neuroimaging appearance of PCNSL differ in immunocompetent patients and in those with acquired immunodeficiency syndrome (AIDS).
  • A magnetic resonance (MR) image of the brain in immunocompetent patients with PCNSL typically demonstrates one or more homogeneously enhancing lesions located in the periventricular white matter, characteristically spanning the corpus callosum.
  • In patients with AIDS, multiple ring-enhancing lesions are more common.
  • After neuroimages raising the suspicion of PCNSL are obtained, a definitive diagnosis should be established in both immunocompetent and AIDS patients by performing pathological analysis of cerebrospinal fluid (CSF), vitreous fluid, or a biopsy specimen.
  • Brain biopsy sampling remains the gold standard for PCNSL diagnosis in all patients, although the possibility of establishing routine, minimally invasive diagnostic procedures in which Epstein-Barr virus polymerase chain reaction (PCR) analysis of the CSF and nuclear imaging are used is currently under investigation in the population of patients with AIDS.
  • At the time of diagnosis, the patient should undergo further evaluation, which should include a physical examination, ophthalmic evaluation with a slit-lamp examination, serum lactate dehydrogenase levels, human immunodeficiency virus testing, computed tomography scans of the chest/abdomen/pelvis, bone marrow biopsy sampling, contrast-enhanced brain MR imaging, and lumbar puncture (LP).
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Biopsy. Humans. Magnetic Resonance Imaging. Neoplasm Staging

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134117.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 87
  •  go-up   go-down


23. Yoritaka A, Ohta K, Kishida S: [Prevalence of neurological complications in Japanese patients with AIDS after the introduction of HAART]. Rinsho Shinkeigaku; 2007 Aug;47(8):491-6
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prevalence of neurological complications in Japanese patients with AIDS after the introduction of HAART].
  • We investigated trends in neurological complications of infection with human immunodeficiency virus (HIV) in Japan after the introduction of highly active antiretroviral therapy (HAART).
  • Two questionnaire surveys were performed in hospitals treating acquired immunodeficiency syndrome (AIDS) to compare two periods: immediately after the introduction of HAART (1999-2001); and a few years later (2002-3).
  • Neurological complications developed as the first AIDS-defining disease for 8.3% of AIDS patients in 1999-2001 and for 5.4% in 2002-3.
  • However, prevalences of cytomegalovirus encephalitis, PML and primary brain lymphoma did not decrease.
  • PML and primary brain lymphoma occurred in patients who received HAART and whose CD4 counts were relatively high during the study period.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Central Nervous System Diseases / epidemiology
  • [MeSH-minor] AIDS Arteritis, Central Nervous System / epidemiology. AIDS-Associated Nephropathy / epidemiology. AIDS-Related Complex / epidemiology. Humans. Japan / epidemiology. Prevalence. Surveys and Questionnaires

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882940.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Kim HW, Won KS, Choi BW, Zeon SK: Cerebral Toxoplasmosis in a Patient with AIDS on F-18 FDG PET/CT. Nucl Med Mol Imaging; 2010 Apr;44(1):75-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral Toxoplasmosis in a Patient with AIDS on F-18 FDG PET/CT.
  • The distinction between primary central nervous system (CNS) lymphoma and nonmalignant lesions due to opportunistic infections, in particular cerebral toxoplasmosis, is important because of the different treatments involved.
  • A 32-year-old patient with AIDS was hospitalized for intermittent headaches.
  • Brain magnetic resonance imaging (MRI) showed a small well-enhanced nodular lesion in the right frontal lobe.
  • We present a case of cerebral toxoplasmosis in a patient with acquired immunodeficiency syndrome (AIDS) and the usefulness of F-18 FDG PET/CT in the differential diagnosis of the cerebral toxoplasmosis will be discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24899941.001).
  • [ISSN] 1869-3474
  • [Journal-full-title] Nuclear medicine and molecular imaging
  • [ISO-abbreviation] Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC4042964
  • [Keywords] NOTNLM ; AIDS / CT / Cerebral toxoplasmosis / FDG / PET
  •  go-up   go-down


25. Scrigni A, Nastri M, Rodríguez de Schiavi S, Czornyj L, Felice M, Mantese B: Leptomeningeal lymphoma in a child with acquired immune deficiency syndrome. Neuropediatrics; 2006 Jun;37(3):121-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal lymphoma in a child with acquired immune deficiency syndrome.
  • Primary non-Hodgkin lymphoma of the central nervous system is rare in pediatric AIDS patients.
  • We report a seven-year-old HIV-infected boy, in stage C3 of the disease, who developed non-Hodgkin lymphoma in the central nervous system with a leptomeningeal location.
  • The diagnosis was based on brain biopsy, immunophenotypic studies of B cells, and Epstein-Barr virus serology of the cerebrospinal fluid.
  • Fifteen months after diagnosis he had clinically improved, but he then relapsed with a thalamic tumor.
  • In the present article, we discuss diagnostic difficulties, evolution, treatment, and the association of this neoplasm with the Epstein-Barr virus.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, Non-Hodgkin / etiology. Meningeal Neoplasms / etiology


26. Young RJ, Ghesani MV, Kagetsu NJ, Derogatis AJ: Lesion size determines accuracy of thallium-201 brain single-photon emission tomography in differentiating between intracranial malignancy and infection in AIDS patients. AJNR Am J Neuroradiol; 2005 Sep;26(8):1973-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lesion size determines accuracy of thallium-201 brain single-photon emission tomography in differentiating between intracranial malignancy and infection in AIDS patients.
  • BACKGROUND AND PURPOSE: Discrimination between enhancing mass lesions in acquired immunodeficiency syndrome (AIDS) patients with conventional CT and MR imaging remains difficult.
  • We determined the effect of lesion size on thallium-201 brain single-photon emission tomography (SPECT) imaging in differentiating primary brain lymphoma from cerebral toxoplasmosis.
  • METHODS: We retrospectively identified 35 AIDS patients with a total of 48 focal enhancing mass lesions on contrast-enhanced brain CT and/or MR images who subsequently underwent thallium-201 brain SPECT imaging.
  • RESULTS: Malignant lesions in 20 patients had a mean thallium index of 2.4 (range, 1-11).
  • Twenty-five lesions were <2 cm (14 malignant, 11 nonmalignant) and 23 lesions were > or =2 cm (14 malignant, 9 nonmalignant).
  • CONCLUSION: Lesion size is a significant determinant of the accuracy of thallium-201 brain SPECT imaging, which should be the initial diagnostic tool for lesions > or =2 cm.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Brain Diseases / diagnosis. Brain Neoplasms / diagnosis. Infection / diagnosis. Thallium Radioisotopes. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. ROC Curve. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155145.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thallium Radioisotopes
  •  go-up   go-down


27. Rubenstein J, Ferreri AJ, Pittaluga S: Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma; 2008;49 Suppl 1:43-51
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment.
  • An overview of the current approaches to the management of patients with primary central nervous system lymphoma (PCNSL) is provided.
  • Although accumulating evidence demonstrates that PCNSL is a curable type of brain tumor, in many cases establishing the diagnosis and overcoming chemotherapeutic resistance remain significant obstacles.
  • The introduction of highly active antiretroviral therapy has had a major impact on this disease in that the incidence of AIDS-related central nervous system lymphoma, once highly prevalent in the 1980s and 1990s, has now virtually disappeared.
  • The use of anti-CD20 antibody in this disease represents the first application of biologically based targeted therapies for PCNSL; however, the overall impact of this modality in brain lymphoma awaits further evaluation in ongoing studies The application of proteomic as well as gene expression technologies is yielding insights into PCNSL pathogenesis, in particular specific oncogenic pathways, which may be exploited to develop new therapies.
  • [MeSH-major] Central Nervous System Neoplasms. Lymphoma

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 1998 Feb;50(2):335-40 [9484350.001]
  • [Cites] Stereotact Funct Neurosurg. 1995;64(4):183-96 [8817805.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1819-20 [15533914.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):207-15 [15621803.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1065-72 [15709173.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2233-9 [15800313.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):293-9 [15980688.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5718-27 [16009945.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2446-54 [16286384.001]
  • [Cites] Blood. 2006 Jan 1;107(1):190-6 [16150948.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1152-6 [16489068.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Neurology. 2006 May 9;66(9):1435-8 [16682682.001]
  • [Cites] Surg Neurol. 2006 Nov;66(5):503-6 [17084198.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):199-201 [10563423.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):742-9 [11157026.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):14-25 [11554386.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):995-9 [11598169.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1372-9 [11684953.001]
  • [Cites] Acta Neuropathol. 2001 Nov;102(5):489-95 [11699563.001]
  • [Cites] Neurology. 2002 May 28;58(10):1513-20 [12034789.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):531-8 [12056702.001]
  • [Cites] Neurology. 2002 Sep 10;59(5):762-4 [12221174.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1504-10 [12237919.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):258-65 [12548175.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2407-14 [12805341.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:275-92 [14971583.001]
  • [Cites] Neurosurg Focus. 2006;21(5):E1 [17134111.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1350-6 [17312328.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Sep;63(3):257-68 [17590348.001]
  • [Cites] Cancer. 2007 Oct 15;110(8):1803-14 [17721992.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4730-5 [17947720.001]
  • [Cites] Ann Oncol. 2007 Nov;18(11):1851-5 [17804469.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):96-105 [18056677.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3200-10 [18184868.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1869-75 [14592832.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2933-5 [15238418.001]
  • [Cites] Neurology. 1993 Nov;43(11):2358-62 [8232956.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • (PMID = 18821432.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 51
  • [Other-IDs] NLM/ NIHMS612828; NLM/ PMC4110179
  •  go-up   go-down


28. Costa H, Franco M, Hahn MD: Primary lymphoma of the central nervous system: a clinical-pathological and immunohistochemical study of ten autopsy cases. Arq Neuropsiquiatr; 2006 Dec;64(4):976-82
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the central nervous system: a clinical-pathological and immunohistochemical study of ten autopsy cases.
  • CONTEXT: Primary central nervous system lymphomas (PCNSL) are a rare subgroup of lymphomas generally associated with HIV and EBV.
  • METHOD: The clinical, histological and immunohistochemical data of ten cases of PCNSL, eight cases from patients with AIDS, identified among 265 autopsies of these patients were analyzed.
  • Most patients had diffuse large B cell non-Hodgkins lymphoma.
  • The lack of detection of the virus might have been due to the long time of fixation of the brain which might have inactivate epitopes therefore compromising the testing.
  • CONCLUSION: In the present series, PCNSL presented with focal symptoms, with unifocal or multifocal lesions, with a predominant B-cell CD20 positive phenotype, rarely associated with EBV.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adult. Autopsy. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / virology. Female. Humans. Immunohistochemistry. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / virology. Male. Middle Aged

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17221007.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


29. Klass CM, Krug LT, Pozharskaya VP, Offermann MK: The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood; 2005 May 15;105(10):4028-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production.
  • Primary effusion lymphoma (PEL) is a B-cell lymphoma in which human herpesvirus-8 (HHV-8) is found within all tumor cells and represents a target for selectively destroying tumor cells.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Foscarnet .
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1999 Feb 1;18(3):644-53 [9927424.001]
  • [Cites] J Gen Virol. 1999 Jan;80 ( Pt 1):83-90 [9934688.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] J Virol. 1999 Jun;73(6):4786-93 [10233939.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):165-74 [10343068.001]
  • [Cites] J Virol. 1999 Sep;73(9):7334-42 [10438822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8 [12145325.001]
  • [Cites] Virology. 1999 Sep 15;262(1):18-30 [10489337.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Prog Neurobiol. 1999 May;58(1):31-59 [10321796.001]
  • [Cites] Mol Cell. 2004 Mar 12;13(5):713-23 [15023341.001]
  • [Cites] J Virol. 2004 Jun;78(12):6621-35 [15163753.001]
  • [Cites] J Virol. 2004 Aug;78(15):8359-71 [15254208.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):391-8 [15289507.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1393-400 [10555008.001]
  • [Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] J Virol. 2000 Jan;74(2):684-92 [10623730.001]
  • [Cites] J Clin Virol. 2000 May;16(3):215-24 [10738140.001]
  • [Cites] Eur J Biochem. 2000 May;267(9):2768-77 [10785400.001]
  • [Cites] AIDS. 2000 May 5;14(7):899-902 [10839602.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Immunity. 2000 Jul;13(1):129-41 [10933401.001]
  • [Cites] Trends Microbiol. 2000 Sep;8(9):410-8 [10989308.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2000 Dec;74(23):10920-9 [11069986.001]
  • [Cites] J Virol. 2000 Dec;74(24):11977-82 [11090200.001]
  • [Cites] J Virol. 2001 Feb;75(3):1487-506 [11152521.001]
  • [Cites] J Virol. 2001 Mar;75(6):2938-45 [11222719.001]
  • [Cites] J Virol. 2001 Jul;75(13):6193-8 [11390621.001]
  • [Cites] J Hum Virol. 2001 Mar-Apr;4(2):62-73 [11437316.001]
  • [Cites] J Virol. 2001 Aug;75(16):7572-82 [11462029.001]
  • [Cites] Adv Cancer Res. 2002;84:155-74 [11883526.001]
  • [Cites] Brain Tumor Pathol. 2001;18(2):109-14 [11908866.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2141-53 [11948397.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13745-51 [11830587.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12):1736-44 [12085319.001]
  • [Cites] Med Res Rev. 2002 Sep;22(5):492-511 [12210556.001]
  • [Cites] Neuropharmacology. 2002 Dec;43(7):1158-64 [12504922.001]
  • [Cites] AIDS. 2003 Jan 24;17(2):215-22 [12545082.001]
  • [Cites] Apoptosis. 2003 Jun;8(3):237-49 [12766484.001]
  • [Cites] J Virol. 2003 Jul;77(14):8147-52 [12829853.001]
  • [Cites] Nature. 2003 Jul 31;424(6948):516-23 [12872134.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]
  • [Cites] Toxicology. 2003 Nov 5;192(2-3):219-27 [14580788.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1079-86 [14871841.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] J Gen Virol. 2004 Oct;85(Pt 10):2779-87 [15448338.001]
  • [Cites] Drugs. 1991 Jan;41(1):104-29 [1706982.001]
  • [Cites] Am J Med. 1992 Feb 14;92(2A):8S-11S [1371039.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]
  • [Cites] J Infect Dis. 1996 Jul;174(1):188-90 [8655992.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):53-7 [8686762.001]
  • [Cites] Drugs. 1996 Jul;52(1):17-32 [8799682.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1996 Sep;32(8):505-13 [8889605.001]
  • [Cites] J Virol. 1997 Mar;71(3):1984-91 [9032330.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] Curr Opin Pediatr. 1997 Feb;9(1):24-30 [9088751.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2082-6 [9151779.001]
  • [Cites] J Virol. 1997 Jun;71(6):4193-8 [9151805.001]
  • [Cites] J Clin Invest. 1997 Nov 15;100(10):2606-10 [9366576.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 17;89(24):1868-74 [9414174.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Feb;42(2):293-7 [9527775.001]
  • [Cites] Neuropsychopharmacology. 1998 Sep;19(3):194-9 [9653707.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • (PMID = 15687238.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R0-1 CA 79402
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Nucleic Acid Synthesis Inhibitors; 0 / RNA, Messenger; 0 / Viral Proteins; 364P9RVW4X / Foscarnet; 614OI1Z5WI / Valproic Acid; EC 2.7.7.7 / DNA-Directed DNA Polymerase; P9G3CKZ4P5 / Ganciclovir
  • [Other-IDs] NLM/ PMC1895088
  •  go-up   go-down


30. Cavaliere R, Petroni G, Lopes MB, Schiff D, International Primary Central Nervous System Lymphoma Collaborative Group: Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer; 2010 Feb 15;116(4):863-70
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.
  • BACKGROUND: Primary central nervous system (CNS) post-transplantation lymphoproliferative disorder (PCNS-PTLD) is a rare complication of solid organ transplantation.
  • METHODS: The authors reviewed the databases of participating institutions of the International Primary CNS Lymphoma Collaborative Group for cases of PCNS-PTLD.
  • RESULTS: The median time from transplantation to diagnosis of PCNS-PTLD was 4.4 years.
  • Disease usually was multifocal and involved any location of the brain but was most common in the cerebral hemispheres, usually in the subcortical white matter or basal ganglia.
  • Cerebral biopsy was required to establish diagnosis in most patients.
  • CONCLUSIONS: The current study demonstrated that PCNS-PTLD is typically an EBV-induced B-cell lymphoma that is responsive to treatment with favorable survival in many patients.
  • An aggressive approach to tissue confirmation of diagnosis and treatment with chemotherapy or radiotherapy should be strongly considered.
  • [MeSH-major] Central Nervous System Diseases / epidemiology. Immunosuppressive Agents / adverse effects. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / epidemiology. Organ Transplantation / adverse effects

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2000 Mar;11(3):374-5 [10811510.001]
  • [Cites] Br J Haematol. 2008 Jan;140(2):191-6 [18173755.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):229-38 [11265232.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):360-7 [11555713.001]
  • [Cites] Neurology. 2001 Oct 23;57(8):1486-8 [11673595.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):965-71 [12615710.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1787-93 [12891064.001]
  • [Cites] Transplantation. 2003 Sep 27;76(6):930-7 [14508356.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):246-53 [14983939.001]
  • [Cites] Pediatr Nephrol. 2004 Apr;19(4):369-77 [14986084.001]
  • [Cites] Arch Neurol. 1970 Mar;22(3):226-33 [4904201.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):601-5 [9231685.001]
  • [Cites] AIDS. 1997 Nov 15;11(14):1725-30 [9386807.001]
  • [Cites] Lancet. 1998 Sep 5;352(9130):789 [9737292.001]
  • [Cites] Transplant Proc. 2005 Mar;37(2):954-5 [15848587.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67 [15979320.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3053-7 [16254143.001]
  • [Cites] Pediatr Transplant. 2006 Jun;10(4):505-12 [16712612.001]
  • [Cites] Curr HIV Res. 2006 Jul;4(3):375-8 [16842088.001]
  • [Cites] Nephrology (Carlton). 2006 Aug;11(4):355-66 [16889577.001]
  • [Cites] Am J Transplant. 2006 Nov;6(11):2735-42 [17049061.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1237-41 [17577794.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):364-9 [17522336.001]
  • [Cites] Neurosurgery. 2007 Jul;61(1):130-40; discussion 140-1 [17621028.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4730-5 [17947720.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4902-8 [17971586.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1489-94 [18024397.001]
  • [CommentIn] Cancer. 2010 Jul 15;116(14):3521; author reply 3521-2 [20564159.001]
  • (PMID = 20052713.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13 CA124293
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ NIHMS585616; NLM/ PMC4113953
  •  go-up   go-down


31. Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, Furrer H, Hasse B, Levi F, Probst-Hensch NM, Schmid P, Franceschi S, Swiss HIV Cohort Study: Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS; 2008 Jan 11;22(2):301-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
  • OBJECTIVE: To assess the long-term effect of HAART on non-Hodgkin lymphoma (NHL) incidence in people with HIV (PHIV).
  • HAART use was associated with a decline in NHL incidence [HR = 0.26; 95% confidence interval (CI), 0.20-0.33], and this decline was greater for primary brain lymphomas than other NHL.
  • Among HAART users, only age was significantly associated with NHL risk.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. HIV Infections / drug therapy. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Adult. Age Factors. Antiretroviral Therapy, Highly Active. Brain Neoplasms / epidemiology. Brain Neoplasms / etiology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Cohort Studies. Female. Humans. Incidence. Male. Middle Aged. Risk Factors. Switzerland


32. Serraino D, Zucchetto A, Suligoi B, Bruzzone S, Camoni L, Boros S, De Paoli A, Dal Maso L, Franceschi S, Rezza G: Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study. J Acquir Immune Defic Syndr; 2009 Sep 1;52(1):99-105
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study.
  • OBJECTIVES: To provide survival estimates of Italian people with AIDS (PWA) in the highly active antiretroviral therapy era and to identify prognostic factors at diagnosis and illnesses present at death.
  • Non-Hodgkin lymphoma at AIDS diagnosis was the strongest negative prognostic factor, particularly in the first 12 months after AIDS (hazard ratio = 9.2, for primary brain lymphoma).
  • At death, non-AIDS-defining illnesses increased from 38.4% in 1999 to 56.9% in 2006, with non-AIDS-defining cancers rising from 3.7% to 8.7%.
  • CONCLUSIONS: Our study documented the prolonged survival of Italian PWA, the strong impact of non-Hodgkin lymphoma on mortality, and the increasing frequency of non-AIDS-defining illnesses at death.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Acquired Immunodeficiency Syndrome / mortality
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / mortality. Female. Humans. Italy / epidemiology. Longitudinal Studies. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / mortality. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448558.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Del Valle L, Piña-Oviedo S: HIV disorders of the brain: pathology and pathogenesis. Front Biosci; 2006;11:718-32
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV disorders of the brain: pathology and pathogenesis.
  • Approximately 16,000 new cases are diagnosed every day and almost 3 million people die every year from AIDS, making it the fourth leading cause of death in the world.
  • Since the introduction of highly active anti-retroviral therapy (HAART) in the mid 1990s, the morbidity and mortality associated with HIV-1 infection has significantly decreased and AIDS has become a chronic disorder.
  • However, neuropathological conditions associated with AIDS are still present in approximately 70 to 90% of patients and can be the result of HIV itself or of opportunistic infections.
  • Here we briefly review the pathology and pathophysiology of AIDS-Encephalopathy, of some of the significant opportunistic infections affecting the brain in the context of AIDS, including Progressive Multifocal Leukoencephalopathy (PML) a demyelinating disease caused by the human neurotropic JC virus, Toxoplasmosis, Cryptococcosis and of primary CNS lymphoma, a brain malignancy frequently associated with HIV-1 infection, all of them considered AIDS defining conditions.
  • [MeSH-major] AIDS-Related Opportunistic Infections / virology. Brain / virology. Brain Diseases / virology. HIV Infections / pathology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome. Animals. Antiretroviral Therapy, Highly Active. Central Nervous System Neoplasms / virology. Cryptococcosis / virology. HIV-1 / chemistry. Humans. JC Virus / chemistry. Leukoencephalopathy, Progressive Multifocal / virology. Toxoplasmosis / virology


34. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Touloumi G, Miro JM, Chene G, Lundgren J, Egger M: Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS; 2009 Sep 24;23(15):2029-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy.
  • OBJECTIVE: We examined survival and prognostic factors of patients who developed HIV-associated non-Hodgkin lymphoma (NHL) in the era of combination antiretroviral therapy (cART).
  • Patients had to have a CD4 cell count after 1 January 1998 and one at diagnosis of the NHL.
  • Survival at 1 year was 66% [95% confidence interval (CI) 63-70%] for systemic NHL (n = 763) and 54% (95% CI: 43-65%) for primary brain lymphoma (n = 84).
  • Patients developing NHL on cART had an increased risk of death compared with patients who were cART naive at diagnosis.
  • CONCLUSION: In the era of cART two-thirds of patients diagnosed with HIV-related systemic NHL survive for longer than 1 year after diagnosis.
  • Survival is poorer in patients diagnosed with primary brain lymphoma.
  • More advanced immunodeficiency is the dominant prognostic factor for mortality in patients with HIV-related NHL.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV-1. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality


35. Paul T, Challa S, Tandon A, Panigrahi M, Purohit A: Primary central nervous system lymphomas: Indian experience, and review of literature. Indian J Cancer; 2008 Jul-Sep;45(3):112-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphomas: Indian experience, and review of literature.
  • Primary central nervous system lymphomas (PCNSLs) are a rare form of non-Hodgkin's lymphoma which arise within and remain confined primarily to the central nervous system (CNS).
  • They generally account for 1-2% of all primary brain tumors and are reported to be on the rise due to the Acquired Immune Deficiency Syndrome (AIDS) epidemic.
  • Presence of lymphadenopathy, organomegaly and bone marrow study was done to exclude the possibility of secondary involvement by lymphoma.
  • The diagnosis was confirmed by histopathology with Hematoxylin and Eosin and reticulin stains.
  • The immune status was evaluated by clinical examination and human immunodeficiency virus (HIV) serology (since 1996).
  • There was a single case of CD 3 positive T-cell lymphoma.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018115.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


36. Lamers SL, Salemi M, Galligan DC, Morris A, Gray R, Fogel G, Zhao L, McGrath MS: Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain. J Neurovirol; 2010 May;16(3):230-41
LANL HIV Databases. LANL HIV Databases .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain.
  • The interplay between pathology and human immunodeficiency virus (HIV) expansion in brain tissues has not been thoroughly assessed in the highly active antiretroviral therapy (HAART) era.
  • HIV-associated dementia (HAD) is marked by progressive brain infection due to recruitment and migration of macrophages in brain tissues; however, the cellular and viral events occurring prior to HAD development and death are under debate.
  • In this study, 66 brain tissues from 11 autopsies were analyzed to assess HIV-1 DNA concentration in brain tissues.
  • In most patients without HAD, it was impossible to amplify HIV-1 from brain tissues.
  • Amplifiable DNA was obtained from three cases of patients on HAART who died due to primary pathology other than HAD:.
  • (1) cardiovascular disease, a disease associated with HAART therapy;.
  • (2) bacterial infections, including Mycobacterium avium complex, rapid occurrence of extreme dementia; and (3) acquired immunodeficiency syndrome (AIDS)-related lymphoma with meningeal involvement.
  • Analysis of HIV-1 nef, gp120, and gp41 sequences showed reduced viral evolution within brain tissues for the non-HAD cases relative to patients with clinical and histological HAD.
  • The present study is the first to show a potential correlation between HIV-1 evolutionary patterns in the brain and different neuropathologies.

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Symptom Management .
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • HIV InSite. treatment guidelines - Mycobacterium avium Complex and Atypical Mycobacterial Infections in the Setting of HIV Infection .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1999 Oct 22;13(15):2055-9 [10546857.001]
  • [Cites] Glia. 2009 May;57(7):734-43 [18985732.001]
  • [Cites] J Leukoc Biol. 2000 Sep;68(3):303-10 [10985244.001]
  • [Cites] Clin Infect Dis. 2000 Dec;31(6):1488-92 [11096017.001]
  • [Cites] J Clin Microbiol. 2001 Jan;39(1):298-303 [11136787.001]
  • [Cites] Neurology. 2001 Jan 23;56(2):257-60 [11160967.001]
  • [Cites] J Exp Med. 2001 Apr 16;193(8):905-15 [11304551.001]
  • [Cites] Circulation. 2001 Jul 17;104(3):257-62 [11457741.001]
  • [Cites] Neurology. 2001 Aug 14;57(3):542-4 [11502933.001]
  • [Cites] Annu Rev Neurosci. 2002;25:537-62 [12052920.001]
  • [Cites] Am Heart J. 2002 Oct;144(4):642-8 [12360160.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] Lancet. 2002 Nov 30;360(9347):1747-8 [12480430.001]
  • [Cites] J Neurovirol. 2002 Dec;8 Suppl 2:115-21 [12491162.001]
  • [Cites] J Virol. 2003 Nov;77(22):12336-45 [14581570.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):1993-2003 [14627784.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Dec;27 Suppl 3:S35-40 [14704742.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):436-8 [14960476.001]
  • [Cites] Circulation. 2004 Apr 6;109(13):1603-8 [15023877.001]
  • [Cites] J Virol. 1993 Sep;67(9):5623-34 [8350415.001]
  • [Cites] Clin Exp Immunol. 1994 Jul;97(1):76-82 [8033423.001]
  • [Cites] Ann Neurol. 1995 Nov;38(5):755-62 [7486867.001]
  • [Cites] AIDS. 1995 Sep;9(9):1001-8 [8527071.001]
  • [Cites] Ann Neurol. 1996 Mar;39(3):392-5 [8602761.001]
  • [Cites] Nature. 1996 Jun 20;381(6584):661-6 [8649511.001]
  • [Cites] Science. 1996 Jun 28;272(5270):1955-8 [8658171.001]
  • [Cites] Clin Rev Allergy Immunol. 1996-1997 Winter;14(4):359-66 [9040966.001]
  • [Cites] J Virol. 1998 Mar;72(3):2509-15 [9499115.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12574-9 [9770527.001]
  • [Cites] J Infect Dis. 1999 May;179 Suppl 3:S457-60 [10099119.001]
  • [Cites] J Neuroimmunol. 1999 Aug 3;98(2):185-200 [10430052.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):69-81 [15630430.001]
  • [Cites] Curr HIV Res. 2005 Jan;3(1):53-60 [15638723.001]
  • [Cites] Neurotox Res. 2004;6(7-8):503-21 [15639783.001]
  • [Cites] Virus Res. 2005 Aug;111(2):194-213 [15885841.001]
  • [Cites] J Neurovirol. 2005 Apr;11(2):107-28 [16036790.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Expert Rev Mol Med. 2005 Dec 2;7(27):1-26 [16321172.001]
  • [Cites] Am Heart J. 2006 Jun;151(6):1147-55 [16781213.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34 [16878047.001]
  • [Cites] J Virol. 2007 Jun;81(12):6643-51 [17428864.001]
  • [Cites] Mol Biol Evol. 2007 Aug;24(8):1596-9 [17488738.001]
  • [Cites] Int Rev Psychiatry. 2008 Feb;20(1):3-13 [18240058.001]
  • [Cites] IEEE/ACM Trans Comput Biol Bioinform. 2008 Apr-Jun;5(2):291-300 [18451438.001]
  • [Cites] J Neurovirol. 2008 Aug;14(4):318-26 [18780233.001]
  • [Cites] Curr HIV Res. 2008 Sep;6(5):388-400 [18855649.001]
  • [Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]
  • [Cites] PLoS One. 2009;4(3):e5065 [19333384.001]
  • [Cites] J Infect Dis. 2000 Apr;181(4):1486-90 [10762582.001]
  • (PMID = 20367240.001).
  • [ISSN] 1538-2443
  • [Journal-full-title] Journal of neurovirology
  • [ISO-abbreviation] J. Neurovirol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA066529-12; United States / NICHD NIH HHS / HD / HD32259; United States / NIAID NIH HHS / AI / R01 AI065265; United States / NINDS NIH HHS / NS / NS063897-01A2; United States / NIMH NIH HHS / MH / MH073510-01; United States / NIMH NIH HHS / MH / R01 MH073510; United States / NCI NIH HHS / CA / U01 CA066529; United States / NIMH NIH HHS / MH / R01 MH073510-01; United States / NICHD NIH HHS / HD / R01 HD032259; United States / NIAID NIH HHS / AI / AI065265; United States / NINDS NIH HHS / NS / R01 NS063897-01A2; United States / NINDS NIH HHS / NS / R01 NS063897
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / HIV Core Protein p24; 0 / HIV Envelope Protein gp120; 0 / HIV Envelope Protein gp41; 0 / Human Immunodeficiency Virus Proteins; 0 / gp120 protein, Human immunodeficiency virus 1; 0 / nef Gene Products, Human Immunodeficiency Virus; 0 / nef protein, Human immunodeficiency virus 1; 0 / p24 protein, Human Immunodeficiency Virus Type 1
  • [Other-IDs] NLM/ NIHMS225058; NLM/ PMC2994721
  •  go-up   go-down


37. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Chene G, Egger M: Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther; 2009;14(8):1065-74
HAL archives ouvertes. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.
  • BACKGROUND: Incidence and risk factors of HIV-associated non-Hodgkin's lymphoma (NHL) are not well defined in the era of combination antiretroviral therapy (cART).
  • RESULTS: During the 212,042 person-years of follow-up, 521 patients were diagnosed with systemic NHL and 62 with primary brain lymphoma (PBL).
  • Suppression of HIV-1 replication on cART (HR 0.60, 95% CI 0.44-0.81, comparing < or =500 with 10,000-99,999 copies/ml) and increases in CD4(+) T-cell counts (HR 0.30, 0.22-0.42, comparing > or =350 with 100-199 cells/microl) were protective; a history of Kaposi's sarcoma (HR 1.70, 1.08-2.68, compared to no history of AIDS), transmission through sex between men (HR 1.57, 1.19-2.08, compared with heterosexual transmission) and older age (HR 3.71, 2.37-5.80, comparing > or =50 with 16-29 years) were risk factors for systemic NHL.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Brain Neoplasms / epidemiology. HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Dec 15;282(23):2220-6 [10605973.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] AIDS. 2001 Aug 17;15(12):1483-91 [11504980.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Br J Cancer. 2001 Nov 2;85(9):1298-303 [11720464.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Antivir Ther. 2004 Aug;9(4):631-3 [15456095.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Am J Epidemiol. 1994 Feb 15;139(4):362-8 [8109570.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] AIDS. 1996 Feb;10(2):181-5 [8838706.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Arch Intern Med. 2005 Feb 28;165(4):416-23 [15738371.001]
  • [Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Clin Infect Dis. 2006 Feb 1;42(3):411-7 [16392091.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):377-80 [17372233.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] Antivir Ther. 2007;12(6):931-9 [17926647.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1350-7 [18042691.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] AIDS. 2008 Feb 19;22(4):489-96 [18301061.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Clin Infect Dis. 2008 Aug 1;47(3):410-7 [18582203.001]
  • [Cites] AIDS. 2008 Jul 31;22(12):1463-73 [18614870.001]
  • [Cites] JAMA. 2008 Aug 6;300(5):555-70 [18677028.001]
  • [Cites] Clin Infect Dis. 2008 Nov 1;47(9):1209-15 [18808357.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4834-42 [18591544.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):537-48 [19017178.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Clin Infect Dis. 2009 Mar 1;48(5):633-9 [19202627.001]
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • (PMID = 20032536.001).
  • [ISSN] 2040-2058
  • [Journal-full-title] Antiviral therapy
  • [ISO-abbreviation] Antivir. Ther. (Lond.)
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0700820
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ HALMS394577; NLM/ PMC2821596
  • [Investigator] Antinori A; Bonnet F; Boué F; Brockmeyer N; Casabona J; Costagliola D; Dronda F; Obel N; Fätkenheuer G; Fisher M; Franceschi S; Gibb D; Le Moing V; Mocroft A; Nadal D; Touloumi G; Prins M; Raffi F; Roca B; Verbon A; Wolf T; Fortuny C; Bohlius J; Chakraborty R; Clifford G; Egger M; Franceschi S; May M; Minder C; Sterne J; Zwahlen M; Ellefson M; Kjaer J; Collin F; Colin C; Weller I; Costagliola D; Ledergerber B; Lundgren J; Chene G; Touloumi G; Warszawski J; Meyer L; Dabis F; Krause MM; Goujard C; Leport C; de Wolf F; Reiss P; Porter K; Dorrucci M; Sabin C; Gibb D; Del Amo J; Obel N; Thorne C; Mocroft A; Kirk O; Staszewski S; Perez-Hoyos S; Almeda J; Antinori A; Monforte Ad; de Martino M; Brockmeyer N; Fätkenheuer G; Ramos J; Battegay M; Mussini C; Tookey P; Casabona J; Miro JM; Castagna A; de Wit S; Torti C; Teira R; Garrido M; Dedes N; Sabin C; Phillips A; Furrer H; Kirk O; Egger M; Dabis F; Newell M; Sterne J; Telenti A; Pantazis N; Lechenadec J; Jérôme F; Tran L; Balestre E; Lanoy E; Couturier F; Rispens T; Gras LA; Bhaskaran K; Sabin C; Hill T; Judd A; Duong T; Sobrino P; Obel N; Thorne C; Kjaer J; Jennings B; Pérez-Hoyos S; Almeda J; Bonfigli S; Cozzi-Lepri A; Corvasce S; Adorni F; Ridolfo AL; Paraninfo G; Ramos JT; Keiser O; Borghi V; Masters J; Ortiga B; Salpietro S; Rickenbach M; Poll B; Garrido M
  •  go-up   go-down


38. Kleinschmidt-DeMasters BK, Damek DM, Lillehei KO, Dogan A, Giannini C: Epstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications. J Neuropathol Exp Neurol; 2008 Nov;67(11):1103-11
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications.
  • Unlike primary central nervous system lymphomas (PCNSLs) in patients with AIDS or organ transplants, PCNSLs in the elderly are usually not considered to be mediated by Epstein Barr virus (EBV); hence, diagnostic studies for EBV are not routinely performed.
  • We encountered 4 patients, 65 years or older, who developed EBV-associated PCNSLs and who had been treated with a variety of immunosuppressive drugs for different autoimmune/collagen vascular disorders, including autoimmune polyneuropathy (mycophenolate mofetil for 5 years), polymyositis (prednisone for 16 years with intermittent methotrexate, azathioprine, and cyclophosphamide), myasthenia gravis (azathioprine >10 years), and rheumatoid arthritis (methotrexate >10 years).
  • All patients had multifocal, necrotic brain lesions typical of EBV-positive PCNSLs on neuroimaging.
  • The patient who had received mycophenolate mofetil was treated successfully for his EBV-associated PCNSL with rituximab and methotrexate, but later developed fatal systemic malignant melanoma, which was likely immunosuppression related.
  • The striking feature of these cases is the variety of underlying diseases-and hence accompanying medications-that can be associated with EBV-associated PCNSLs.
  • [MeSH-major] Central Nervous System Neoplasms / physiopathology. Epstein-Barr Virus Infections / physiopathology. Immune Tolerance / physiology. Lymphoma / physiopathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18957891.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Immunoglobulin Heavy Chains; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


39. Yoganathan K: A 'brain tumor' in an intravenous drug abuser. Int J Gen Med; 2009;2:73-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 'brain tumor' in an intravenous drug abuser.
  • Clinically brain tumor was suspected but a brain biopsy confirmed cerebral toxoplasmosis.
  • An HIV test was not considered until the result of brain biopsy.
  • He deteriorated after a brain biopsy.
  • Clinical features and differential diagnosis of cerebral toxoplasmosis in immunocompromised patients are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1643-8 [1359410.001]
  • [Cites] Int J STD AIDS. 2006 Apr;17(4):271-6 [16595052.001]
  • [Cites] AIDS. 1994 Dec;8(12):1691-4 [7888118.001]
  • [Cites] Medicine (Baltimore). 1994 Nov;73(6):306-14 [7984082.001]
  • [Cites] AIDS. 1995 Nov;9(11):1243-50 [8561977.001]
  • [Cites] AIDS. 1996 Nov;10(13):1521-7 [8931787.001]
  • [Cites] J Neurol. 1997 Jan;244(1):35-9 [9007743.001]
  • [Cites] Acta Neurol Scand. 1999 Nov;100(5):332-6 [10536922.001]
  • [Cites] Clin Infect Dis. 2000 Mar;30(3):491-9 [10722433.001]
  • [Cites] J Infect. 2000 May;40(3):274-81 [10908023.001]
  • [Cites] Neurology. 2000 Oct 24;55(8):1194-200 [11071499.001]
  • [Cites] Neuroimaging Clin N Am. 2003 May;13(2):237-50, x-xi [13677804.001]
  • [Cites] Cancer Treat Rev. 2003 Dec;29(6):533-40 [14585263.001]
  • [Cites] J Clin Microbiol. 2005 Oct;43(10):5044-7 [16207959.001]
  • [Cites] Ann Neurol. 1986 Mar;19(3):224-38 [3963767.001]
  • (PMID = 20360890.001).
  • [ISSN] 1178-7074
  • [Journal-full-title] International journal of general medicine
  • [ISO-abbreviation] Int J Gen Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2840556
  • [Keywords] NOTNLM ; HIV/AIDS / brain tumor / cerebral toxoplasmosis / intravenous drug abuser / primary brain lymphoma
  •  go-up   go-down


40. Sokolska V, Knysz B, Czapiga E, Gasiorowski J, Sasiadek M, Gładysz A: [The role of brain magnetic resonance studies in the diagnostics of central nervous system lesions in HIV-1 positive patients]. Wiad Lek; 2006;59(11-12):805-13
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of brain magnetic resonance studies in the diagnostics of central nervous system lesions in HIV-1 positive patients].
  • Approximately 10% of persons infected with human immunodeficiency virus (HIV) and 75-90% patients with acquired immunodeficiency syndrome (AIDS) present neurological symptoms.
  • This group causes the greatest diagnostic difficulties among AIDS patients.
  • The purpose of the study was to demonstrate the usefulness of the magnetic resonance imaging (MR) of the central nervous system (CNS) in the diagnosis and differentiation of primary and secondary lesions.
  • In 40 of them AIDS diagnosis was established based on the picture of CNS lesions.
  • RESULTS: Pathological findings were visible on MR of CNS in 37 (92.5%) of 40 patients with AIDS.
  • In 8 (20%) cases the diagnosis of AIDS dementia complex (ADC) was established.
  • Toxoplasmosis was diagnosed in 9 (22.5%) cases, tuberculosis in 6 (15%), cryptococcosis in 5 (12.5%) patients, progressive multifocal leukoencephalopathy (PML) in 3 (7.5%) patients, primary lymphoma also in 3 (7.5%), and atypical mycobacteriosis in 2 patient.
  • In 1 (2.5%) case we could not establish the final diagnosis.
  • It is very useful, together with the results of other tests, in the final diagnosis of the lesions in the CNS.
  • Magnetic resonance plays also an important role in the treatment planning and monitoring of the efficacy of therapy used in AIDS patients.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Acquired Immunodeficiency Syndrome / complications. Brain Diseases / diagnosis. HIV Seropositivity / complications. Magnetic Resonance Imaging
  • [MeSH-minor] AIDS Dementia Complex / diagnosis. Adult. Brain. Diagnosis, Differential. Female. Humans. Leukoencephalopathy, Progressive Multifocal / diagnosis. Lymphoma, AIDS-Related / diagnosis. Male. Meningitis, Cryptococcal / diagnosis. Middle Aged. Toxoplasmosis, Cerebral / diagnosis


41. Correa RM, Fellner MD, Durand K, Redini L, Alonio V, Yampolsky C, Colobraro A, Sevlever G, Teyssié A, Benetucci J, Picconi MA: Epstein Barr virus genotypes and LMP-1 variants in HIV-infected patients. J Med Virol; 2007 Apr;79(4):401-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 30-bp deletion in latent membrane protein-1 gene (del-LMP-1) has been identified in various pathologies.
  • The study was performed on 258 individuals: CASES: 144 HIV-infected patients that included: (a) 7 AIDS patients with primary central nervous system lymphoma (PCNSL), (b) 62 AIDS patients, and (c) 75 asymptomatic HIV-infected patients.
  • EBV genotypes and variants in LMP-1 gene were detected by polymerase chain reaction (PCR)-Southern blot on DNA extracted from peripheral blood mononuclear cells and brain biopsies.
  • Del-LMP-1 was found in 44.4% of HIV-infected patients samples (20.7% alone and 23.7% co-infection with non-deleted form) while it was found in 25.3% (6.3% alone and 19% with co-infection) in HIV-negative individuals.
  • In all, PCNSL brain biopsies samples, del-LMP-1 always was detected with EBV-2, but more cases would have to be included to draw definitive conclusions.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Adolescent. Adult. Argentina. Base Sequence. Biopsy. Blotting, Southern. Brain / pathology. Brain / virology. Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / pathology. Genetic Variation. Humans. Leukocytes, Mononuclear / virology. Lymphoma, AIDS-Related / complications. Male. Middle Aged. Polymerase Chain Reaction. Sequence Deletion. Species Specificity

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17311329.001).
  • [ISSN] 0146-6615
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


42. Choe PG, Park WB, Song JS, Song KH, Jeon JH, Park SW, Kim HB, Chang KH, Oh MD, Choe KW, Kim NJ: Spectrum of intracranial parenchymal lesions in patients with human immunodeficiency virus infection in the Republic of Korea. J Korean Med Sci; 2010 Jul;25(7):1005-10
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of intracranial parenchymal lesions in patients with human immunodeficiency virus infection in the Republic of Korea.
  • At the time of the diagnosis of intracranial parenchymal lesions, median CD4(+) lymphocyte count was 40 cells/microL (range 5-560) and in 33 (82.5%) patients, it was less than 200 cells/microL.
  • Progressive multifocal leukoencephalopathy (12 patients) is the most frequent intracranial parenchymal lesions, followed by intracranial tuberculoma (7 patients), primary central nervous system lymphoma (7 patients), intracranial cryptococcoma (4 patients), Toxoplasma encephalitis (4 patients), and disseminated non-tuberculous mycobacterial infection (3 patients).
  • [MeSH-major] AIDS-Related Opportunistic Infections / pathology. Central Nervous System Diseases / pathology. Central Nervous System Diseases / virology. HIV Infections / pathology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 1999 Dec;29(6):1524-8 [10585807.001]
  • [Cites] J Korean Med Sci. 1999 Oct;14(5):469-74 [10576140.001]
  • [Cites] Clin Infect Dis. 2000 Apr;30(4):710-8 [10770733.001]
  • [Cites] Acta Neuropathol. 2000 Aug;100(2):213-20 [10963370.001]
  • [Cites] Clin Infect Dis. 2000 Aug;31(2):619-20 [10987736.001]
  • [Cites] Neurology. 2000 Oct 24;55(8):1194-200 [11071499.001]
  • [Cites] J Neurovirol. 2002 Oct;8(5):432-8 [12402169.001]
  • [Cites] J Neurovirol. 2002 Dec;8 Suppl 2:115-21 [12491162.001]
  • [Cites] J Korean Med Sci. 2003 Apr;18(2):149-57 [12692408.001]
  • [Cites] Yonsei Med J. 2003 Jun 30;44(3):363-70 [12833572.001]
  • [Cites] Eur J Neurol. 2004 May;11(5):297-304 [15142222.001]
  • [Cites] Curr Opin Neurol. 2004 Jun;17(3):365-70 [15167073.001]
  • [Cites] J Neurosurg. 1985 Apr;62(4):475-95 [2983051.001]
  • [Cites] Ann Intern Med. 1986 Aug;105(2):210-3 [3729203.001]
  • [Cites] Ann Intern Med. 1987 Jul;107(1):78-87 [3296901.001]
  • [Cites] Arch Pathol Lab Med. 1990 Jul;114(7):643-55 [2194443.001]
  • [Cites] J Infect Dis. 1992 Dec;166(6):1408-11 [1331253.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):995-1000 [8366923.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Apr;24(2):118-24 [9634207.001]
  • [Cites] Neurology. 1999 Jan 15;52(2):253-60 [9932940.001]
  • [Cites] Clin Infect Dis. 1999 May;28(5):1152-4 [10452651.001]
  • [Cites] Clin Infect Dis. 2005 Apr 1;40(7):1049-52 [15825000.001]
  • [Cites] Korean J Parasitol. 2005 Jun;43(2):69-71 [15951643.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] Korean J Parasitol. 2009 Jun;47(2):125-30 [19488418.001]
  • [Cites] AIDS. 2000 Jan 7;14(1):69-74 [10714569.001]
  • (PMID = 20592890.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2890875
  • [Keywords] NOTNLM ; Acquired Immunodeficiency Syndrome / Brain Diseases / HIV / Korea
  •  go-up   go-down


43. Aiello-Laws L, Rutledge DN: Management of adult patients receiving intraventricular chemotherapy for the treatment of leptomeningeal metastasis. Clin J Oncol Nurs; 2008 Jun;12(3):429-35
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer in the central nervous system can arise from a primary brain tumor and metastasize to the brain or to the leptomeninges, leading to leptomeningeal metastasis (LM).
  • Nursing care of patients with LM requires an understanding of neurologic anatomy and physiology, along with associated treatments and complications.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Adult. Blepharoptosis / etiology. Brain Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / nursing. Carcinoma / secondary. Drug Compounding. Drug Monitoring / nursing. Evidence-Based Medicine. Fatal Outcome. Humans. Low Back Pain / etiology. Lymphoma, AIDS-Related / complications. Male. Muscle Weakness / etiology. Nurse's Role. Nursing Assessment. Practice Guidelines as Topic

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18515241.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  • [Number-of-references] 30
  •  go-up   go-down


44. Rollins KE, Kleinschmidt-DeMasters BK, Corboy JR, Damek DM, Filley CM: Lymphomatosis cerebri as a cause of white matter dementia. Hum Pathol; 2005 Mar;36(3):282-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary central nervous system lymphoma most often presents as a solitary, isolated lesion in immunocompetent patients.
  • CT features of primary cerebral lymphoma in AIDS and non-AIDS patients.
  • Primary intracranial CNS lymphoma: MR manifestations.
  • 1993;10:725-9) demonstrated nonnecrotic, diffusely infiltrating, large-cell B-cell lymphoma of white matter, with relative sparing of gray matter, and without significant leptomeningeal involvement or bulky periventricular disease at autopsy.
  • Microglial and astrocytic reactions, but only subtle myelin pallor, were evident as individual tumor cells permeated the entire brain and spinal cord, albeit with considerable variation in cell density.
  • Individual tumor cells could be identified from the optic nerve to spinal cord, documenting the "whole-brain" nature of the disease.
  • CD20 immunostaining was necessary to fully appreciate the extent of individual lymphoma cell percolation through the white matter.
  • The neurobehavioral deficits manifested by these patients demonstrate that lymphomatosis cerebri is an additional neoplastic cause of white matter dementia and can be added to the growing list of disorders responsible for this syndrome.
  • [MeSH-major] Central Nervous System Neoplasms / complications. Dementia / etiology. Lymphoma / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Astrocytes / pathology. Biopsy. Brain / pathology. Dementia, Vascular / etiology. Dementia, Vascular / pathology. Fatal Outcome. Female. Humans. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / pathology. Magnetic Resonance Imaging. Male. Microglia / pathology. Middle Aged. Optic Nerve / pathology. Spinal Cord / pathology

  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791573.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Kumar GG, Mahadevan A, Guruprasad AS, Kovoor JM, Satishchandra P, Nath A, Ranga U, Shankar SK: Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature. J Magn Reson Imaging; 2010 Jun;31(6):1469-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cerebral toxoplasmosis remains one of the most common focal brain lesions in patients with acquired immune deficiency syndrome (AIDS).
  • Diagnosis is a challenge because on cranial imaging it closely mimics central nervous system lymphoma, primary and metastatic central nervous system (CNS) tumors, or other intracranial infections like tuberculoma or abscesses.
  • Herein we correlate the underlying histopathology to the MR feature of eccentric target sign in a patient with autopsy-proven HIV/AIDS-related cerebral toxoplasmosis.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Med Res. 2000 Jan;111:14-23 [10793489.001]
  • [Cites] Ann Neurol. 1986 Mar;19(3):224-38 [3963767.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1653-63 [7502971.001]
  • [Cites] Semin Roentgenol. 2007 Apr;42(2):62-91 [17394921.001]
  • [Cites] Neuroimaging Clin N Am. 1997 May;7(2):171-86 [9113684.001]
  • [Cites] Indian J Med Res. 2005 Apr;121(4):468-88 [15817957.001]
  • [Cites] Clin Radiol. 2006 May;61(5):393-401 [16679111.001]
  • [Cites] J Comput Assist Tomogr. 1996 May-Jun;20(3):417-22 [8626904.001]
  • (PMID = 20512900.001).
  • [ISSN] 1522-2586
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS055628-01A2; United States / NINDS NIH HHS / NS / R01 NS055628; United States / NINDS NIH HHS / NS / 1R01NS055628-01A2; United States / NINDS NIH HHS / NS / R01 NS055628-01A2
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS218257; NLM/ PMC2908244
  •  go-up   go-down


46. Caro-Murillo AM, Gil Luciano A, Navarro Rubio G, Leal Noval M, Blanco Ramos JR, Cohorte de la Red de Investigación en Sida (CoRIS): [HIV infection in different age groups: Potential implications for prevention. CoRIS Cohort, Spain, 2004-2008]. Med Clin (Barc); 2010 Apr 24;134(12):521-7
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Infección por el virus de la inmunodeficiencia humana en diferentes grupos de edad: implicaciones potenciales para la prevención. Cohorte CoRIS, España, 2004-2008.
  • We analyzed their characteristics at recruitment and the distribution of AIDS defining illnesses (ADI) prior to cohort entry and during follow up, according to their age at recruitment.
  • Delayed diagnosis was defined as a patient with AIDS diagnosis and/or CD4+ cell count lower than 200 cells/microl within the first year after HIV diagnosis.
  • RESULTS: Of 4,418 patients included, 30.4% were < or =30 years old, 60.6% between 31 and 50 and 8.9% older than 50 at cohort entry; 31.6% of patients were immigrants (44.1% in the youngest group), 79.6% had been sexually transmitted and 15.2% had an AIDS diagnosis at cohort entry (28.1% between those older than 50).
  • In 34.6% of cases there was a late diagnosis (53.3% in the oldest group).
  • Pneumocystis jiroveci pneumonia, progressive multifocal leukoencephalopathy, HIV related encephalopathy, recurrent pneumonia and primary lymphoma of brain were more frequent among the oldest.
  • The proportion of late diagnosis was unacceptably high, suggesting the need of specific interventions designed to promote earlier diagnosis.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / diagnosis. Acquired Immunodeficiency Syndrome / epidemiology. Adolescent. Adult. Age Factors. Child. Child, Preschool. Cohort Studies. Data Interpretation, Statistical. Female. Health Surveys. Humans. Male. Middle Aged. Prospective Studies. Sex Factors. Socioeconomic Factors. Spain / epidemiology. Time Factors. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier España, S.L. All rights reserved.
  • [CommentIn] Med Clin (Barc). 2010 May 8;134(13):587-8 [20207372.001]
  • (PMID = 20207371.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Investigator] Berenguer J; del Amo J; García F; Gutiérrez F; Labarga P; Moreno S; Muñoz MA; Caro-Murillo AM; Vegas PS; Pérez-Cachafeiro S; Sebastián VH; Ferreras BA; Trastoy M; Muñoz MA; García I; Sogorb JP; Merino de Lucas E; Bañuls SR; Martínez VB; Oncina LG; Pastor CG; Tamarit IP; Sirvent JL; Fotúnez PR; Valls MR; Socas Mdel M; Lirola AM; Hernández MI; Calzadilla CH; Soriano V; Labarga P; Barreiro P; Castañares C; Rivas P; Ruiz A; Blanco F; García P; de Diego M; Asensi V; Valle E; Cartón JA; Miro JM; López-Dieguez M; Manzardo C; Zamora L; García JF; Agüero F; Sánchez V; Blanco JL; García-Alcaide F; Martínez E; Mallolas J; Gatell J; Rubio R; Pulido F; Fiorante S; Llenas J; Iribarren JA; Arrizabalaga J; Aramburu MJ; Camino X; Rodríguez-Arrondo F; von Wichmann MA; Tomé LP; Goenaga MA; Bustinduy MJ; Gutiérrez F; Masiá M; Ramos JM; Padilla S; Sánchez V; Escolano C; Montolio F; Peral Y; Clotet B; Tural C; Ruiz L; Miranda C; Muga R; Tor J; Sanvisens A; Berenguer J; Bernaldo de Quirós JC; Miralles P; Ochaíta JC; Conde MS; Cuellar IG; Schacke MR; Ortega BP; Vidal F; Peraire J; Viladés C; Veloso S; Sanjuan M; Vargas M; López-Dupla M; Olona M; Aldeguer JL; Juliá MB; Rodrigo JL; Salavert M; Montero M; Calabuig E; Cuéllar S; García JG; Bernardino de la Serna I; Sánchez de Rivera JM; Rillo MM; López JR; Ramírez ML; Pareja JF; Arribas B; Castro JM; Jara RM; de los Santos I; Sanz JS; Rodríguez J; Oteo JA; Blanco J; Ibarra V; Metola L; Sanz M; Pérez-Martínez L; Moraza JP; Catalán AP; Paesa CR; Garés PA; Pérez DG; Dalmau D; Manzanera AJ; Llobell MC; Puig DI; Bellés PV; Montañez QJ; Valls MX; Martínez-Lacasa J; Rodríguez CS; Alemany JG; Font R; Boneta JS; Uriz J; Castiello J; Reparaz J; Arraiza MJ; Irigoyen C; Segura F; Amengual MJ; Penelo E; Navarro G; Sala M; Cervantes M; Pineda V; Moreno S; Casado JL; Dronda F; Moreno A; Elías MJ; López D; Gutiérrez C; Hernández B; Pumares M; Martí P; Sánchez AC; Morell EB; Pérez AM; García FG; Quero JH; Monje AP; Medina LM; Ruiz JP; Guerrero Jdel R; Martín CR; García S; Ruano MD; Antela A; Prieto A; Losada E; Riera M; Murillas J; Peñaranda M; Leyes M; Ribas MA; Campins A; Villalonga C; Pineda JA; Sánchez ER; Lozano de León F; Macías J; del Valle J; Gómez-Mateos J; González JS; Solero MM; Ramos IV; Muñoz RP; Viciana P; Leal M; López-Cortés LF; Trastoy M; Alcázar-Caballero RM
  •  go-up   go-down


47. Chang LJ, Liu X, He J: Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Gene Ther; 2005 Jul;12(14):1133-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
  • The high mutation rate of the human immunodeficiency virus (HIV) makes it difficult for any therapy employing a single anti-HIV targeting mechanism to sustain prolonged effect.
  • In an attempt to explore novel therapy for AIDS, we developed and tested lentiviral small interfering RNA (siRNA) vectors targeting multiple highly conserved regions in the HIV type 1 (HIV-1) genome.
  • Transduction of a long-term chronically infected human lymphoma cell line with lentiviral siRNAs resulted in stable inhibition of HIV-1 replication.
  • In addition, the viral RNA was inhibited in both the nuclear and cytoplasmic compartments of [corrected] chronically infected cells after prolonged passage, suggesting that [corrected] lentiviral siRNAs have a nuclear effect [corrected] Using these lentiviral siRNA [corrected] vectors, we further demonstrated reduced replication kinetics of HIV-1 in primary human peripheral blood lymphocytes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Gene Ther. 2005 Aug;12(16):1289
  • (PMID = 15750613.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / RNA, Viral
  •  go-up   go-down






Advertisement